lamotrigine has been researched along with Absence Seizure in 247 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 9.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "We report outcomes from an open-label, non-randomized, 24-week study of eslicarbazepine acetate (ESL) in adults at earlier and later stages of their treatment history for focal seizures, conducted in a real-world clinical setting." | 9.41 | Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures. ( Blum, D; Cantu, D; Gidal, B; Grinnell, T; Hixson, J; Mehta, D; Pikalov, A; Zhang, Y, 2021) |
| "To investigate the efficacy and safety of long-term lamotrigine (LTG) monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures." | 9.27 | Long-term efficacy and safety of lamotrigine monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures: An open-label extension study. ( Kurata, A; Numachi, Y; Ohtsuka, Y; Sato, K; Shimizu, M; Yasumoto, S, 2018) |
| "To evaluate and compare the effects of concomitant lamotrigine (LTG) or carbamazepine (CBZ) on the incidence of treatment-emergent adverse events (TEAEs) in patients taking adjunctive eslicarbazepine acetate (ESL) for focal (partial-onset) seizures (FS)." | 9.27 | Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures. ( Abou-Khalil, B; Blum, D; Cheng, H; Gama, H; Grinnell, T; Jung, J; Klein, P; Rocha, F; Ryvlin, P; Shah, A; Specchio, LM, 2018) |
| " Adults with partial-onset seizures must have been taking either carbamazepine/oxcarbazepine (CBZ/OXC), lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA)." | 9.20 | Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. ( Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015) |
| "To determine the tolerability and efficacy of lamotrigine extended-release (LTG XR) as adjunctive therapy with optional conversion to monotherapy in patients ages≥65 years with epilepsy." | 9.19 | Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy. ( Hammer, AE; Huffman, R; Leroy, R; Messenheimer, JA; Van Cott, A; VanLandingham, K; Vuong, A; Wechsler, RT, 2014) |
| "Four-hundred and thirty-four patients with partial seizures were randomized to pregabalin, lamotrigine, or placebo as adjunctive therapy for 17 weeks of double-blind treatment." | 9.14 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "Efficacy and tolerability of once-daily adjunctive lamotrigine extended-release (XR) for primary generalized tonic-clonic (PGTC) seizures in epilepsy were evaluated." | 9.14 | Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. ( Adams, B; Biton, V; Demchenko, V; Di Memmo, J; Hammer, A; Lee, YY; Messenheimer, J; Poverennova, I; Saiers, J; Shukla, R; Vuong, A, 2010) |
| "These analyses, conducted on a data set drawn from a previously reported, open-label, multicentre, prospective study, examined the effect of lamotrigine on mood in adults aged>or=50 years with epilepsy and co-morbid depressive symptoms." | 9.13 | Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study. ( Fakhoury, TA; Hammer, AE; Miller, JM; Vuong, A, 2008) |
| "To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures (AS), when compared with placebo or each other." | 9.12 | Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. ( Brigo, F; Igwe, SC; Lattanzi, S, 2021) |
| "Lamotrigine was an effective and well-tolerated treatment for seizures associated with the Lennox-Gastaut syndrome." | 9.08 | Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. ( Arvidsson, JF; Barrera, MN; Manasco, P; Motte, J; Mullens, EL; Trevathan, E, 1997) |
| "This systematic review and meta-analysis of randomized controlled trials (RCTs) systematically explored the effectiveness and safety of lamotrigine for absence seizures in children and adolescents." | 9.05 | The efficacy and safety of lamotrigine for absence seizures in children and adolescents: A systematic review and meta-analysis. ( Cao, J; Lin, XX; Liu, H; Ma, XM, 2020) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 8.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| "To report a case of acute pediatric lamotrigine ingestion resulting in seizures." | 8.86 | Seizures secondary to lamotrigine toxicity in a two-year-old. ( Banks, CJ; Close, BR, 2010) |
| "Lamotrigine is an antiepileptic drug which is believed to suppress seizures by inhibiting the release of excitatory neurotransmitters." | 8.78 | Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. ( Chrisp, P; Goa, KL; Ross, SR, 1993) |
| " In the present work, BCRP's role as a mechanism that might contribute to drug-resistant epilepsy (DRE) in a mouse model of acute seizures was studied with further assessment of the effect of its inhibition by ko143 and metformin (MET) on lamotrigine (LTG) bioavailability and efficacy." | 8.31 | Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine. ( El-Sayed, NS; Fathelbab, MH; Harby, SA; Khalil, NA; Saleh, SR; Thabet, EH, 2023) |
| "Maintaining seizure control with lamotrigine is complicated by altered pharmacokinetics and existence of subpopulations in whom clearance increases or remains constant during pregnancy." | 8.31 | Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. ( Barry, JM; Birnbaum, AK; French, JA; Harden, CL; Karanam, A; Pennell, PB, 2023) |
| "AbstractThe aim of this study was to explore the effect of lamotrigine (LTG) on blood ammonia level in patients with epilepsy and identify risk factors affecting blood ammonia level." | 8.12 | Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine. ( Chen, J; Chen, X; Chen, Y; Miao, J; Wang, R; Zeng, J; Zhuang, X, 2022) |
| "Lamotrigine and lacosamide show similar effectiveness in diffuse glioma patients with epilepsy." | 8.02 | The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. ( Dirven, L; Fiocco, M; Koekkoek, JAF; Kouwenhoven, MCM; Taphoorn, MJB; van den Bent, MJ; van der Meer, PB; van Opijnen, MP, 2021) |
| "Strikingly, 47% of 62 lithium plus psychedelic reports involved seizures, and an additional 18% resulted in bad trips while none of 34 lamotrigine reports did." | 8.02 | Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. ( Barrett, FS; Erowid, E; Erowid, F; Griffiths, RR; Gukasyan, N; Nayak, SM, 2021) |
| "This study was carried out to determine changes over time in use of folic acid, anti-epileptic drugs (AED), seizures during pregnancy and malformation rate over two decades in women with epilepsy enrolled in the Kerala registry of Epilepsy and Pregnancy (KREP)." | 7.96 | Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. ( A S, R; Baishya, J; Jose, M; Keni, RR; Sankara Sarma, P; Thomas, SV, 2020) |
| "Clinicians should use caution interpreting lamotrigine levels when working up delirium, as normal levels may not rule out the development of lamotrigine toxicity." | 7.96 | Delirium Secondary to Lamotrigine Toxicity. ( Catalano, G; Catalano, MC; Fusick, AJ; Gunther, SR; Hernandez, MJ; Sanchez, DL; Sullivan, GA, 2020) |
| "To evaluate the pharmacokinetic changes in lamotrigine (LTG) from prepregnancy to postpartum and to assess the impact of therapeutic drug monitoring (TDM) on seizure management during pregnancy in a Chinese population." | 7.91 | Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy. ( Ding, Y; Guo, Y; Tan, X; Zhang, S, 2019) |
| "Cannabidiol and cannabidiol-enriched products have recently attracted much attention as an add-on therapy for epilepsy, especially drug-resistant seizures." | 7.91 | Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. ( Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019) |
| "The aim of the study was to determine anticonvulsant activity of lamotrigine (LTG) after acute and chronic treatment in four different protocols against maximal electroshock-induced seizures in mice." | 7.81 | Effects of Chronic Lamotrigine Administration on Maximal Electroshock- Induced Seizures in Mice. ( Banach, M; Borowicz, KK, 2015) |
| "Levetiracetam (LEV), used for both partial and generalized seizures, is a frequently preferred antiepileptic because of its few side effects." | 7.80 | Hypokalemia and hypomagnesaemia related to levetiracetam use. ( Aksoy, D; Cevik, B; Kurt, S; Pekdas, E; Solmaz, V, 2014) |
| " Lamotrigine (LTG) is an effective clinical treatment for epilepsy associated with absence seizures." | 7.78 | Lamotrigine ameliorates seizures and psychiatric comorbidity in a rat model of spontaneous absence epilepsy. ( Chen, SD; Huang, HY; Lee, HW; Shaw, FZ, 2012) |
| "Lamotrigine (LTG) has shown to confer broad-spectrum, well-tolerated control of epilepsy." | 7.75 | Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy. ( Hardison, HH; Khurana, DS; Kothare, SV; Legido, A; Marks, HG; Melvin, JJ; Piñol-Ripoll, G; Valencia, I, 2009) |
| "This case is the first report of a patient who had phenobarbital (PB) withdrawal seizures after having been seizure-free for 3 years following temporal lobe surgery." | 7.75 | Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism. ( Bidlack, JM; Morris, HH, 2009) |
| "Using a retrospective chart review, we identified six patients with epilepsy who reported transient emergent psychological symptoms during stable, chronic lamotrigine monotherapy." | 7.75 | End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. ( Frey, LC; Shrestha, A; Spitz, MC; Strom, LA, 2009) |
| "In a trial including 38 children, lamotrigine, which had to be introduced very gradually in order to reduce the risk of potentially severe skin reactions, took longer than valproic acid to control typical absence seizures." | 7.75 | Lamotrigine and absence seizures: new indication. Try valproic acid first. ( , 2009) |
| "A case of lamotrigine-induced seizures in a pediatric patient is reported, with a level approximately five times the upper limit of the therapeutic range." | 7.74 | Lamotrigine-induced seizures in a child: case report and literature review. ( Anderson, IB; Olson, KR; Stewart, PJ; Thundiyil, JG, 2007) |
| "The aim of this study was to characterize outcomes in patients with epilepsy who experienced adverse reactions on switching from branded to generic lamotrigine and who were subsequently switched back to the branded formulation." | 7.74 | Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. ( Makus, KG; McCormick, J, 2007) |
| "Isobolographic profile of interactions between lamotrigine (LTG) and felbamate (FBM), two second-generation antiepileptic drugs, against maximal electroshock (MES)-induced seizures, and neurotoxic adverse effects in the chimney test in mice were determined." | 7.73 | Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. ( Czuczwar, SJ; Luszczki, JJ, 2005) |
| "To describe successful oral bromocriptine therapy for hyperprolactinemia accompanied by seizure disorder and encephalomalacia identified during infertility evaluation." | 7.73 | Hyperprolactinemia presenting with encephalomalacia-associated seizure disorder and infertility: a novel application for bromocriptine therapy in reproductive endocrinology. ( Saie, DJ; Sills, ES, 2005) |
| "To determine whether the efficacy and tolerability of adjunctive lamotrigine differ as a function of whether persons with mental retardation and refractory epilepsy resided in institutions or the community." | 7.73 | Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation. ( Hammer, AE; McKee, JR; Sunder, TR; Vuongc, A, 2006) |
| " Anticonvulsant effects were evaluated against seizures induced by both 14 mg/kg of 4-aminopyridine and 110 mg/kg of pentylenetetrazole, and neurotoxic effects were evaluated by the rotarod test." | 7.72 | Synergistic interaction between felbamate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice. ( Armijo, JA; Bravo, J; Cuadrado, A, 2003) |
| " Anticonvulsant effects were evaluated against seizures induced by both 4-aminopyridine and pentylenetetrazole, and neurotoxic effects were evaluated by the rotarod test." | 7.71 | Synergistic interaction between valproate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice. ( Armijo, JA; Cuadrado, A; de las Cuevas, I; Valdizán, EM, 2002) |
| "To determine the tolerability of lamotrigine in elderly patients with epilepsy." | 7.71 | The tolerability of lamotrigine in elderly patients with epilepsy. ( Giorgi, L; Gomez, G; Hammer, AE; O'Neill, F; Risner, M, 2001) |
| "We investigated the anticonvulsant and adverse behavioral effects of lamotrigine (LTG), a novel antiepileptic drug (AED), as well as other conventional AEDs on kindled seizures in rats." | 7.70 | Effects of lamotrigine and conventional antiepileptic drugs on amygdala- and hippocampal-kindled seizures in rats. ( Kuroda, S; Morimoto, K; Otsuki, K; Sato, K; Yamada, N, 1998) |
| " Pilocarpine administration has been used as an animal model for temporal lobe epilepsy since it produces several morphological and synaptic features in common with human complex partial seizures." | 7.69 | NMDA receptor-mediated pilocarpine-induced seizures: characterization in freely moving rats by microdialysis. ( Ebinger, G; Khan, GM; Manil, J; Michotte, Y; Smolders, I, 1997) |
| "The effect of lamotrigine, a novel potential antiepileptic drug, upon the development of kindled cortical seizures was investigated in rats." | 7.68 | The effect of lamotrigine upon development of cortical kindled seizures in the rat. ( Miller, AA; O'Donnell, RA, 1991) |
| "Four adult men with resistant partial seizures underwent an intensive open-label protocol designed to evaluate long-term add-on lamotrigine (LTG) therapy." | 7.67 | Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ( Ashworth, M; Keally, M; Kupferberg, H; Mikati, MA; Osborne-Shafer, P; Schachter, SC; Schomer, DL; Seaman, CA; Sheridan, PH; Valakas, A, 1989) |
| "The time to reach individual baseline seizure count was longer in patients with focal seizures receiving ESL as a first (Arm 1) versus later (Arm 2) adjunctive therapy (p = 0." | 7.30 | Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial. ( Aboumatar, S; Cantu, D; Grinnell, T; Krishnaiengar, SR; Zhang, Y, 2023) |
| " Patients were converted during an lamotrigine via a protocol-specified dosing algorithm or to conventional therapy via standard dosing guidelines." | 6.71 | Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. ( Hammer, AE; Kaminow, L; Schimschock, JR; Vuong, A, 2003) |
| "The duration and frequency of seizure activities and electrographic seizure onset of 41 patients totally withdrawing from CBZ monotherapy (n = 20), LTG monotherapy (n = 10) and CBZ + LTG combined therapy (n = 11) were intensively studied by therapeutic intensive seizure analysis (TISA) method." | 6.71 | Changes of seizures activity during rapid withdrawal of lamotrigine. ( Koebnick, C; Pauli, E; Stefan, H; Tilz, C; Wang, B; Wang-Tilz, Y, 2005) |
| "Carbamazepine was ineffective, and seizures were exacerbated with levetiracetam (LEV)." | 5.56 | Improvement of epilepsy with lacosamide in a patient with ring chromosome 20 syndrome. ( Goji, A; Kagami, S; Mori, T; Tayama, T; Toda, Y, 2020) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 5.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 5.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "We report outcomes from an open-label, non-randomized, 24-week study of eslicarbazepine acetate (ESL) in adults at earlier and later stages of their treatment history for focal seizures, conducted in a real-world clinical setting." | 5.41 | Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures. ( Blum, D; Cantu, D; Gidal, B; Grinnell, T; Hixson, J; Mehta, D; Pikalov, A; Zhang, Y, 2021) |
| "Tonic hind limb extension (seizure activity) was evoked in adult male albino Swiss mice by a current (sine-wave, 25 mA, 500 V, 50 Hz, 0." | 5.39 | Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Florek-Luszczki, M; Karwan, S; Luszczki, JJ; Wlaz, A, 2013) |
| "Falling due to startle-induced seizures (SISs) often leads to injury." | 5.37 | Lamotrigine is favourable for startle-induced seizures. ( Fujiwara, T; Ikeda, H; Imai, K; Inoue, Y; Shigematsu, H; Shishido, T; Takahashi, Y; Takayama, R, 2011) |
| "Lamotrigine (LTG) is an antiepileptic drug, a glutamate release inhibitor, with action at the neuronal voltage-gated sodium channel." | 5.35 | NA+, K+-ATPase activity in the brain of the rats with kainic acid-induced seizures: influence of lamotrigine. ( Ljubicić, D; Pelcić, JM; Simonić, A; Vitezić, D; Vitezić, M; Zupan, G, 2008) |
| " Chronic administration of ETA (12." | 5.35 | Effect of ethacrynic acid on the anticonvulsant activity of the second-generation antiepileptics against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Swiderska, G; Łukawski, K, 2009) |
| " The manufacturer recommends half the dosage of lamotrigine monotherapy when the patient also uses valproate." | 5.35 | Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. ( Aldenkamp, AP; Bootsma, HP; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Savelkoul, M; Schellekens, A; Vos, AM, 2008) |
| "Lamotrigine is a commonly prescribed anticonvulsant medication." | 5.34 | Seizures and altered mental status after lamotrigine overdose. ( Geller, RJ; Schwartz, MD, 2007) |
| "Using an amygdala-kindled seizure paradigm, we evaluated the acute and chronic anticonvulsant effects of lamotrigine (LTG)." | 5.31 | Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: cross-tolerance to carbamazepine but not valproate or diazepam. ( Heynen, T; Krupp, E; Li, XL; Post, RM; Weiss, SR, 2000) |
| "Lamotrigine (LTG) is an anticonvulsant that is currently in use for the treatment of various seizure disorders and that shows promise in the treatment of affective illness." | 5.31 | Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy. ( Krupp, E; Li, XL; Post, RM; Postma, T; Weiss, SR, 2000) |
| "Lamotrigine (LTG) is an antiepileptic drug that is also effective in the treatment of certain psychiatric disorders." | 5.31 | Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders. ( Aroniadou-Anderjaska, V; Braga, MF; Li, H; Post, RM, 2002) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 5.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "A newborn infant with seizures of unknown etiology that were refractory to treatment with phenobarbitone, phenytoin, midazolam, clonazepam, and vigabatrin is reported." | 5.30 | Efficacy of lamotrigine in refractory neonatal seizures. ( Antony, JH; Barr, PA; Buettiker, VE, 1999) |
| "The objective was to assess the efficacy and safety of adjunctive brivaracetam (BRV) with concomitant use of lamotrigine (LTG) or topiramate (TPM) in patients with uncontrolled focal seizures." | 5.27 | Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis. ( Benbadis, S; Diaz, A; Elmoufti, S; Klein, P; Schiemann, J; Whitesides, J, 2018) |
| "Pregnant women with epilepsy on one or more of the following AEDs: lamotrigine, carbamazepine, phenytoin or levetiracetam." | 5.27 | AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies. ( Bagary, M; Coleman, J; D'Amico, M; Denny, E; Dodds, J; Eldridge, S; Greenhill, L; Hard, K; Kelso, A; Khan, KS; Marlin, N; McCorry, D; Middleton, L; Moss, N; Newton, S; Pirie, A; Pullen, A; Rikunenko, R; Roberts, T; Rogozińska, E; Thangaratinam, S; Weckesser, A, 2018) |
| "To investigate the efficacy and safety of long-term lamotrigine (LTG) monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures." | 5.27 | Long-term efficacy and safety of lamotrigine monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures: An open-label extension study. ( Kurata, A; Numachi, Y; Ohtsuka, Y; Sato, K; Shimizu, M; Yasumoto, S, 2018) |
| "To evaluate and compare the effects of concomitant lamotrigine (LTG) or carbamazepine (CBZ) on the incidence of treatment-emergent adverse events (TEAEs) in patients taking adjunctive eslicarbazepine acetate (ESL) for focal (partial-onset) seizures (FS)." | 5.27 | Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures. ( Abou-Khalil, B; Blum, D; Cheng, H; Gama, H; Grinnell, T; Jung, J; Klein, P; Rocha, F; Ryvlin, P; Shah, A; Specchio, LM, 2018) |
| " Adults with partial-onset seizures must have been taking either carbamazepine/oxcarbazepine (CBZ/OXC), lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA)." | 5.20 | Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. ( Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015) |
| "To determine the tolerability and efficacy of lamotrigine extended-release (LTG XR) as adjunctive therapy with optional conversion to monotherapy in patients ages≥65 years with epilepsy." | 5.19 | Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy. ( Hammer, AE; Huffman, R; Leroy, R; Messenheimer, JA; Van Cott, A; VanLandingham, K; Vuong, A; Wechsler, RT, 2014) |
| "To explore the efficacy and safety of the combined therapy of valproic acid (VPA) and lamotrigine (LTG) for various types of epilepsy." | 5.16 | [Efficacy and safety of the combined therapy of valproic acid and lamotrigine for epileptics]. ( Hu, Q; Kang, HC; Li, X; Liu, XY; Liu, ZG; Wang, M; Xu, F; Zeng, Z; Zhu, SQ, 2012) |
| "Four-hundred and thirty-four patients with partial seizures were randomized to pregabalin, lamotrigine, or placebo as adjunctive therapy for 17 weeks of double-blind treatment." | 5.14 | A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. ( Barrett, J; Baulac, M; Leon, T; O'Brien, TJ; Whalen, E, 2010) |
| "Efficacy and tolerability of once-daily adjunctive lamotrigine extended-release (XR) for primary generalized tonic-clonic (PGTC) seizures in epilepsy were evaluated." | 5.14 | Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. ( Adams, B; Biton, V; Demchenko, V; Di Memmo, J; Hammer, A; Lee, YY; Messenheimer, J; Poverennova, I; Saiers, J; Shukla, R; Vuong, A, 2010) |
| "These analyses, conducted on a data set drawn from a previously reported, open-label, multicentre, prospective study, examined the effect of lamotrigine on mood in adults aged>or=50 years with epilepsy and co-morbid depressive symptoms." | 5.13 | Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study. ( Fakhoury, TA; Hammer, AE; Miller, JM; Vuong, A, 2008) |
| "A subsample of 67 adult patients with partial seizures participating in a randomized, double-blind study comparing the cognitive effects of adjunctive lamotrigine (LTG) and adjunctive topiramate (TPM) was administered Performance On-Line (POL) in addition to a battery of neuropsychological tests at baseline, week 8 and week 16 of treatment." | 5.13 | Relative influences of adjunctive topiramate and adjunctive lamotrigine on scanning and the effective field of view. ( Blum, DE; Caldwell, PT; Drazkowski, JF; Hammer, AE; Kustra, RP; Mills, KC, 2008) |
| "To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures (AS), when compared with placebo or each other." | 5.12 | Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. ( Brigo, F; Igwe, SC; Lattanzi, S, 2021) |
| "Good efficiency (at least 50% reduction of crises) has been demonstrated for lamotrigine in children with generalized epilepsy (62." | 5.09 | [Lamotrigine therapy in children. Retrospective study of 32 children]. ( Chabrol, B; Léthel, V; Livet, MO; Mancini, J, 2000) |
| "Lamotrigine was an effective and well-tolerated treatment for seizures associated with the Lennox-Gastaut syndrome." | 5.08 | Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. ( Arvidsson, JF; Barrera, MN; Manasco, P; Motte, J; Mullens, EL; Trevathan, E, 1997) |
| "This systematic review and meta-analysis of randomized controlled trials (RCTs) systematically explored the effectiveness and safety of lamotrigine for absence seizures in children and adolescents." | 5.05 | The efficacy and safety of lamotrigine for absence seizures in children and adolescents: A systematic review and meta-analysis. ( Cao, J; Lin, XX; Liu, H; Ma, XM, 2020) |
| "To determine the effects of lamotrigine on (1) seizures, (2) adverse-effect profile, and (3) cognition and quality of life, compared to placebo, when used as an add-on treatment for people with drug-resistant focal epilepsy." | 5.05 | Lamotrigine add-on therapy for drug-resistant focal epilepsy. ( Bresnahan, R; Marson, AG; Panebianco, M; Ramaratnam, S, 2020) |
| " The treatment of choice for CAE with absence seizures only is ethosuximide." | 5.01 | A Practical Guide to Treatment of Childhood Absence Epilepsy. ( Kessler, SK; McGinnis, E, 2019) |
| "In three randomized double-blind clinical trials, lamotrigine extended-release (lamotrigine XR) was demonstrated to be effective in the adjunctive treatment of intractable partial seizures or primary generalized tonic-clonic seizures and as monotherapy for partial seizures." | 4.89 | Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials. ( Biton, V; Caldwell, PT; Hammer, AE; Messenheimer, JA; Naritoku, D; Shneker, BF; Vuong, A, 2013) |
| " We review the clinical literature which suggests that tolerance can develop to most treatment approaches in bipolar illness and present an animal model of tolerance development to anticonvulsant effects of carbamazepine or lamotrigine on amgydala-kindled seizures." | 4.87 | Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders. ( Post, RM; Weiss, SR, 2011) |
| "Clinically significant side effects of the new anticonvulsants, such as metabolic acidosis from topiramate, autoimmune reactions from lamotrigine, hyponatremia from oxcarbazepine, or psychosis from levitiracetam can cause serious morbidity and mortality if unrecognized." | 4.86 | Emergent complications of the newer anticonvulsants. ( Dang, CV; Nelson, L; Wade, JF; Wasserberger, J, 2010) |
| "To report a case of acute pediatric lamotrigine ingestion resulting in seizures." | 4.86 | Seizures secondary to lamotrigine toxicity in a two-year-old. ( Banks, CJ; Close, BR, 2010) |
| "03 mmol/kg for the induction of seizures), produced a significant reduction in the anticonvulsant effects of carbamazepine, phenobarbital, phenytoin, and valproate against maximal electroshock-induced seizures in mice." | 4.84 | [Caffeine and antiepileptic drugs: experimental and clinical data]. ( Błaszczyk, B; Chrościńska-Krawczyk, M; Czuczwar, SJ; Jankiewicz, K, 2007) |
| "To compare the effects of carbamazepine and lamotrigine monotherapy for people with partial onset seizures or generalized onset tonic-clonic seizures." | 4.83 | A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. ( Chadwick, DW; Gamble, C; Marson, AG; Williamson, PR, 2006) |
| "Three new antiepileptic drugs--vigabatrin, gabapentin, and lamotrigine--provide alternatives in the management of older patients with refractory partial seizures." | 4.79 | Seizure control: how to use the new antiepileptic drugs in older patients. ( Haider, A; Haider, S; Tuchek, JM, 1996) |
| "Since 1994, three new antiepileptic drugs, felbamate, lamotrigene, and gabapentin, have been released for the treatment of epilepsy." | 4.79 | A review of the newer antiepileptic drugs and the ketogenic diet. ( Barron, TF; Hunt, SL, 1997) |
| "Lamotrigine is an antiepileptic drug which is believed to suppress seizures by inhibiting the release of excitatory neurotransmitters." | 4.78 | Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. ( Chrisp, P; Goa, KL; Ross, SR, 1993) |
| "Lamotrigine (LTG), a new anticonvulsant, chemically unrelated to current antiepileptic drugs (AEDs), resembles phenytoin (PHT) and carbamazepine (CBZ) in ability to block hindlimb extension in both the maximal electroshock test and leptazol-induced seizures." | 4.78 | Neurochemical and behavioral aspects of lamotrigine. ( Baxter, MG; Critchley, MA; Leach, MJ, 1991) |
| " Utilizing the model of lamotrigine-resistant seizures, we evaluated whether changes in the expression of sodium channel subunits are responsible for the diminished responsiveness to lamotrigine (LTG) and if miRNAs, may also be associated." | 4.31 | miR-9a-5p expression is decreased in the hippocampus of rats resistant to lamotrigine: A behavioural, molecular and bioinformatics assessment. ( Chmielewska, N; Maciejak, P; Osuch, B; Szyndler, J; Wawer, A; Wicik, Z, 2023) |
| " In the present work, BCRP's role as a mechanism that might contribute to drug-resistant epilepsy (DRE) in a mouse model of acute seizures was studied with further assessment of the effect of its inhibition by ko143 and metformin (MET) on lamotrigine (LTG) bioavailability and efficacy." | 4.31 | Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine. ( El-Sayed, NS; Fathelbab, MH; Harby, SA; Khalil, NA; Saleh, SR; Thabet, EH, 2023) |
| "Maintaining seizure control with lamotrigine is complicated by altered pharmacokinetics and existence of subpopulations in whom clearance increases or remains constant during pregnancy." | 4.31 | Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. ( Barry, JM; Birnbaum, AK; French, JA; Harden, CL; Karanam, A; Pennell, PB, 2023) |
| "Use of valproate and carbamazepine decreased progressively, use of lamotrigine remained relatively static, and the use of levetiracetam increased progressively, whereas the use of topiramate first increased and then fell again, associated with a temporary increase in malformation-associated pregnancy rate." | 4.31 | Changes over 24 years in a pregnancy register - Teratogenicity and epileptic seizure control. ( Eadie, M; Graham, J; Hitchcock, A; Lander, C; O'Brien, T; Perucca, P; Vajda, F, 2023) |
| " In our case series, lamotrigine proved to be less effective and less controllable than other drugs during pregnancy." | 4.12 | [Women with epilepsy before and during pregnancy: a case series of outpatient counseling in a tertiary epilepsy center]. ( Bien, CG; Hagemann, A; Knaak, N; Müffelmann, B, 2022) |
| "AbstractThe aim of this study was to explore the effect of lamotrigine (LTG) on blood ammonia level in patients with epilepsy and identify risk factors affecting blood ammonia level." | 4.12 | Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine. ( Chen, J; Chen, X; Chen, Y; Miao, J; Wang, R; Zeng, J; Zhuang, X, 2022) |
| " Our results suggest an association between disabling seizure occurrence during pregnancy and lamotrigine usage in polytherapy that warrants further evaluation." | 4.12 | Epilepsy and Pregnancy: An Audit of Specialized Care. ( Li, J; Nguyen, DK; Toffa, DH, 2022) |
| " Exanthema as especially clinically relevant adverse drug event was rightly chosen for carbamazepine by 18 (8%) and for lamotrigine by 12 (5%) participants." | 4.02 | Knowledge of epilepsy among German pharmacists. ( Bertsche, A; Bertsche, T; Herziger, B; Jeschke, S; Müller, RM; Neininger, MP, 2021) |
| "Lamotrigine and lacosamide show similar effectiveness in diffuse glioma patients with epilepsy." | 4.02 | The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. ( Dirven, L; Fiocco, M; Koekkoek, JAF; Kouwenhoven, MCM; Taphoorn, MJB; van den Bent, MJ; van der Meer, PB; van Opijnen, MP, 2021) |
| " In this study, the pentylenetetrazole seizure test (PTZ) was performed to assess the effectiveness of four new ASDs: lamotrigine (LTG), topiramate (TPM), felbamate (FBM), and levetiracetam (LEV) in the subsequent stages of seizures in adult fish." | 4.02 | Effects of new antiseizure drugs on seizure activity and anxiety-like behavior in adult zebrafish. ( Doboszewska, U; Guz, L; Pieróg, M; Poleszak, E; Serefko, A; Socała, K; Szopa, A; Wlaź, P; Wyska, E, 2021) |
| "Strikingly, 47% of 62 lithium plus psychedelic reports involved seizures, and an additional 18% resulted in bad trips while none of 34 lamotrigine reports did." | 4.02 | Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. ( Barrett, FS; Erowid, E; Erowid, F; Griffiths, RR; Gukasyan, N; Nayak, SM, 2021) |
| "This study was carried out to determine changes over time in use of folic acid, anti-epileptic drugs (AED), seizures during pregnancy and malformation rate over two decades in women with epilepsy enrolled in the Kerala registry of Epilepsy and Pregnancy (KREP)." | 3.96 | Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy. ( A S, R; Baishya, J; Jose, M; Keni, RR; Sankara Sarma, P; Thomas, SV, 2020) |
| "Clinicians should use caution interpreting lamotrigine levels when working up delirium, as normal levels may not rule out the development of lamotrigine toxicity." | 3.96 | Delirium Secondary to Lamotrigine Toxicity. ( Catalano, G; Catalano, MC; Fusick, AJ; Gunther, SR; Hernandez, MJ; Sanchez, DL; Sullivan, GA, 2020) |
| "To evaluate the pharmacokinetic changes in lamotrigine (LTG) from prepregnancy to postpartum and to assess the impact of therapeutic drug monitoring (TDM) on seizure management during pregnancy in a Chinese population." | 3.91 | Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy. ( Ding, Y; Guo, Y; Tan, X; Zhang, S, 2019) |
| "Cannabidiol and cannabidiol-enriched products have recently attracted much attention as an add-on therapy for epilepsy, especially drug-resistant seizures." | 3.91 | Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. ( Nieoczym, D; Socała, K; Szafarz, M; Wlaź, P; Wyska, E, 2019) |
| "For the anticonvulsant experiment lamotrigine dose-dependently suppressed pentylenetetrazole-induced seizures." | 3.85 | Effect of lamotrigine on seizure development in a rat pentylenetetrazole kindling model. ( Chen, Y; Fang, Z; He, X; Sun, Q; Zhou, L, 2017) |
| "The aim of this study was to determine the effects of 2-methyl-6-(phenylethynyl)pyridine (MPEP - a selective antagonist for the glutamate metabotropic receptor subtype mGluR5) on the protective action of some novel antiepileptic drugs (lamotrigine, oxcarbazepine, pregabalin and topiramate) against maximal electroshock-induced seizures in mice." | 3.83 | Influence of MPEP (a selective mGluR5 antagonist) on the anticonvulsant action of novel antiepileptic drugs against maximal electroshock-induced seizures in mice. ( Florek-Luszczki, M; Kondrat-Wrobel, MW; Luszczki, JJ; Zolkowska, D, 2016) |
| " Lamotrigine (LTG), an AED that is effective for both focal and generalized seizures, has been reported to aggravate seizures in Dravet syndrome." | 3.81 | Lamotrigine can be beneficial in patients with Dravet syndrome. ( Dalic, L; Mullen, SA; Roulet Perez, E; Scheffer, I, 2015) |
| "The aim of the study was to determine anticonvulsant activity of lamotrigine (LTG) after acute and chronic treatment in four different protocols against maximal electroshock-induced seizures in mice." | 3.81 | Effects of Chronic Lamotrigine Administration on Maximal Electroshock- Induced Seizures in Mice. ( Banach, M; Borowicz, KK, 2015) |
| " We evaluated influence of DHA on anticonvulsant activity of AEDs phenytoin, valproate, and lamotrigine in maximal electroshock (MES), pentylenetetrazole (PTZ), and kindling models of epilepsy." | 3.81 | Synergistic effect of docosahexaenoic acid on anticonvulsant activity of valproic acid and lamotrigine in animal seizure models. ( Babapour, V; Gavzan, H; Sardari, S; Sayyah, M, 2015) |
| "Levetiracetam (LEV), used for both partial and generalized seizures, is a frequently preferred antiepileptic because of its few side effects." | 3.80 | Hypokalemia and hypomagnesaemia related to levetiracetam use. ( Aksoy, D; Cevik, B; Kurt, S; Pekdas, E; Solmaz, V, 2014) |
| "To assess the effectiveness of the newer antiepileptic drugs (AEDs)-in particular lamotrigine, topiramate, and levetiracetam-in controlling epileptic seizures in pregnant women." | 3.80 | The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy. ( Eadie, M; Graham, J; Lander, C; O'Brien, T; Vajda, FJ, 2014) |
| "Single intraperitoneal (ip) administration of CYT in a subthreshold dose of 2 mg/kg antagonized the protective activity of ip phenytoin and lamotrigine against MES-induced seizures in mice." | 3.79 | Cytisine inhibits the anticonvulsant activity of phenytoin and lamotrigine in mice. ( Bednarski, J; Mosiewicz, J; Mróz, T; Ognik, J; Styk, A; Tutka, P; Łuszczki, J, 2013) |
| "To analyze seizure control, dose adjustments, and other changes of antiepileptic drug (AED) treatment during pregnancy in a large cohort of women with epilepsy entering pregnancy on monotherapy with carbamazepine, lamotrigine, phenobarbital, or valproate." | 3.79 | Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Tomson, T; Vajda, F, 2013) |
| " Lamotrigine (LTG) is an effective clinical treatment for epilepsy associated with absence seizures." | 3.78 | Lamotrigine ameliorates seizures and psychiatric comorbidity in a rat model of spontaneous absence epilepsy. ( Chen, SD; Huang, HY; Lee, HW; Shaw, FZ, 2012) |
| ": To evaluate the effect of lamotrigine (LMT) on electroconvulsive therapy (ECT)-induced seizures." | 3.77 | Concurrent use of lamotrigine and electroconvulsive therapy. ( Demunter, H; Peuskens, J; Roelens, Y; Sienaert, P; Van Heeringen, C; Vansteelandt, K, 2011) |
| "Lamotrigine (LTG) has shown to confer broad-spectrum, well-tolerated control of epilepsy." | 3.75 | Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy. ( Hardison, HH; Khurana, DS; Kothare, SV; Legido, A; Marks, HG; Melvin, JJ; Piñol-Ripoll, G; Valencia, I, 2009) |
| "This case is the first report of a patient who had phenobarbital (PB) withdrawal seizures after having been seizure-free for 3 years following temporal lobe surgery." | 3.75 | Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism. ( Bidlack, JM; Morris, HH, 2009) |
| "We describe an 11-year-old girl with a seizure disorder who developed fever, rash, rhabdomyolysis, and multiorgan failure 2 weeks after commencing a transition from sodium valproate to lamotrigine therapy." | 3.75 | Life-threatening organ failure after lamotrigine therapy. ( Dargan, PI; Ferguson, LP; Hood, JL; Tibby, SM, 2009) |
| "Using a retrospective chart review, we identified six patients with epilepsy who reported transient emergent psychological symptoms during stable, chronic lamotrigine monotherapy." | 3.75 | End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. ( Frey, LC; Shrestha, A; Spitz, MC; Strom, LA, 2009) |
| "In a trial including 38 children, lamotrigine, which had to be introduced very gradually in order to reduce the risk of potentially severe skin reactions, took longer than valproic acid to control typical absence seizures." | 3.75 | Lamotrigine and absence seizures: new indication. Try valproic acid first. ( , 2009) |
| " We present a 12 years old female who was a known case of idiopathic generalized tonic-clonic convulsion and presented with fever, diarrhea and generalized erythematous eruption after 2 weeks of being under treatment with maintenance doses of Lamotrigine (LTG) and Valproate (VPA)." | 3.74 | Intravenous immunoglobulin in the treatment of lamotrigine- induced toxic epidermal necrolysis. ( Inaloo, S; Serati Shirazi, Z, 2008) |
| "A case of lamotrigine-induced seizures in a pediatric patient is reported, with a level approximately five times the upper limit of the therapeutic range." | 3.74 | Lamotrigine-induced seizures in a child: case report and literature review. ( Anderson, IB; Olson, KR; Stewart, PJ; Thundiyil, JG, 2007) |
| "The aim of this study was to characterize outcomes in patients with epilepsy who experienced adverse reactions on switching from branded to generic lamotrigine and who were subsequently switched back to the branded formulation." | 3.74 | Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. ( Makus, KG; McCormick, J, 2007) |
| " In the mouse pentylenetetrazole induced seizures model, JZP-4 was approximately twice as potent as lamotrigine in prolonging the time to clonus." | 3.74 | In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. ( Eller, M; Foreman, MM; Hanania, T; Stables, JP; Stratton, SC; White, HS; Wilcox, KS, 2008) |
| " Lower doses of valproate and carbamazepine were required to prevent hyperactivity compared to doses required to block tonic-clonic seizures induced by pentylenetetrazole." | 3.73 | Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. ( Arban, R; Brackenborough, K; Gerrard, P; Large, C; Maraia, G; Wilson, A; Winyard, L, 2005) |
| "Isobolographic profile of interactions between lamotrigine (LTG) and felbamate (FBM), two second-generation antiepileptic drugs, against maximal electroshock (MES)-induced seizures, and neurotoxic adverse effects in the chimney test in mice were determined." | 3.73 | Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. ( Czuczwar, SJ; Luszczki, JJ, 2005) |
| "To describe successful oral bromocriptine therapy for hyperprolactinemia accompanied by seizure disorder and encephalomalacia identified during infertility evaluation." | 3.73 | Hyperprolactinemia presenting with encephalomalacia-associated seizure disorder and infertility: a novel application for bromocriptine therapy in reproductive endocrinology. ( Saie, DJ; Sills, ES, 2005) |
| "To determine whether the efficacy and tolerability of adjunctive lamotrigine differ as a function of whether persons with mental retardation and refractory epilepsy resided in institutions or the community." | 3.73 | Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation. ( Hammer, AE; McKee, JR; Sunder, TR; Vuongc, A, 2006) |
| " Anticonvulsant effects were evaluated against seizures induced by both 14 mg/kg of 4-aminopyridine and 110 mg/kg of pentylenetetrazole, and neurotoxic effects were evaluated by the rotarod test." | 3.72 | Synergistic interaction between felbamate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice. ( Armijo, JA; Bravo, J; Cuadrado, A, 2003) |
| "Levetiracetam (LEV) is a new antiepileptic drug with efficacy in partial-onset seizures." | 3.72 | Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence. ( Cavitt, J; Privitera, M, 2004) |
| " Anticonvulsant effects were evaluated against seizures induced by both 4-aminopyridine and pentylenetetrazole, and neurotoxic effects were evaluated by the rotarod test." | 3.71 | Synergistic interaction between valproate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice. ( Armijo, JA; Cuadrado, A; de las Cuevas, I; Valdizán, EM, 2002) |
| "To determine the tolerability of lamotrigine in elderly patients with epilepsy." | 3.71 | The tolerability of lamotrigine in elderly patients with epilepsy. ( Giorgi, L; Gomez, G; Hammer, AE; O'Neill, F; Risner, M, 2001) |
| "We investigated the anticonvulsant and adverse behavioral effects of lamotrigine (LTG), a novel antiepileptic drug (AED), as well as other conventional AEDs on kindled seizures in rats." | 3.70 | Effects of lamotrigine and conventional antiepileptic drugs on amygdala- and hippocampal-kindled seizures in rats. ( Kuroda, S; Morimoto, K; Otsuki, K; Sato, K; Yamada, N, 1998) |
| "We report the cases of two children with cranial diabetes insipidus who were treated with lamotrigine for seizures and who had accompanying changes in desmopressin requirements." | 3.70 | Hyponatraemia associated with lamotrigine in cranial diabetes insipidus. ( Aylett, S; Kirkham, F; Mewasingh, L; Stanhope, R, 2000) |
| "During lamotrigine's premarketing clinical trials, the manufacturer reported several cases of Stevens-Johnson syndrome and TEN." | 3.69 | Suspected lamotrigine-induced toxic epidermal necrolysis. ( Chaffin, JJ; Davis, SM, 1997) |
| "The effects of three new antiepileptic drugs (felbamate, lamotrigine and gabapentin) on the parameters of seizure initiation and termination in one model of reverberatory seizures in the hippocampal-parahippocampal loop in urethane-anesthetized rats were determined." | 3.69 | Effects of felbamate, gabapentin and lamotrigine on seizure parameters and excitability in the rat hippocampus. ( Stringer, JL; Xiong, ZQ, 1997) |
| " Pilocarpine administration has been used as an animal model for temporal lobe epilepsy since it produces several morphological and synaptic features in common with human complex partial seizures." | 3.69 | NMDA receptor-mediated pilocarpine-induced seizures: characterization in freely moving rats by microdialysis. ( Ebinger, G; Khan, GM; Manil, J; Michotte, Y; Smolders, I, 1997) |
| "The anticonvulsant actions of lamotrigine and phenytoin against pentylenetetrazol-induced seizures were compared in laboratory rats during ontogenesis." | 3.68 | Anticonvulsant action of lamotrigine during ontogenesis in rats. ( Kubová, H; Mares, P; Stanková, L, 1992) |
| "The effect of lamotrigine, a novel potential antiepileptic drug, upon the development of kindled cortical seizures was investigated in rats." | 3.68 | The effect of lamotrigine upon development of cortical kindled seizures in the rat. ( Miller, AA; O'Donnell, RA, 1991) |
| "Four adult men with resistant partial seizures underwent an intensive open-label protocol designed to evaluate long-term add-on lamotrigine (LTG) therapy." | 3.67 | Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. ( Ashworth, M; Keally, M; Kupferberg, H; Mikati, MA; Osborne-Shafer, P; Schachter, SC; Schomer, DL; Seaman, CA; Sheridan, PH; Valakas, A, 1989) |
| "The time to reach individual baseline seizure count was longer in patients with focal seizures receiving ESL as a first (Arm 1) versus later (Arm 2) adjunctive therapy (p = 0." | 3.30 | Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial. ( Aboumatar, S; Cantu, D; Grinnell, T; Krishnaiengar, SR; Zhang, Y, 2023) |
| "The classification of seizure types and epilepsies should be examined before selecting the ASMs for each patient with epilepsy." | 3.01 | [Medical Treatment of Epilepsy]. ( Jin, K, 2023) |
| "More than thirty antiseizure medications (ASMs) are available for treating epilepsy." | 2.82 | Therapeutic Basis of Generic Substitution of Antiseizure Medications. ( Elmer, S; Reddy, DS, 2022) |
| "The phenytoin treatment causes cerebellar defect and anemia." | 2.82 | The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches. ( Agrawal, M; Dhurandhar, Y; Panda, SP, 2022) |
| "Seizure freedom (SF) was defined as no seizure recurrence during the 40-week maintenance period of medication." | 2.80 | The effect of recurrent seizures on cognitive, behavioral, and quality-of-life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. ( Heo, K; Kim, MJ; Kim, OJ; Kim, SO; Lee, BI; Lee, HW; Lee, SA; Shin, DJ; Song, HK, 2015) |
| " Patients were converted during an lamotrigine via a protocol-specified dosing algorithm or to conventional therapy via standard dosing guidelines." | 2.71 | Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. ( Hammer, AE; Kaminow, L; Schimschock, JR; Vuong, A, 2003) |
| "The duration and frequency of seizure activities and electrographic seizure onset of 41 patients totally withdrawing from CBZ monotherapy (n = 20), LTG monotherapy (n = 10) and CBZ + LTG combined therapy (n = 11) were intensively studied by therapeutic intensive seizure analysis (TISA) method." | 2.71 | Changes of seizures activity during rapid withdrawal of lamotrigine. ( Koebnick, C; Pauli, E; Stefan, H; Tilz, C; Wang, B; Wang-Tilz, Y, 2005) |
| "Whereas transient, self-limiting seizures are an infrequent but known complication of deep brain stimulation (DBS) implantation surgery, stimulation itself has occasionally been reported to result in seizure activity at delayed time points." | 2.61 | Network Basis of Seizures Induced by Deep Brain Stimulation: Literature Review and Connectivity Analysis. ( Boutet, A; Coblentz, A; Davidson, B; Elias, GJB; Germann, J; Giacobbe, P; Gramer, R; Ibrahim, GM; Jain, M; Kucharczyk, W; Lozano, AM; Wennberg, RA, 2019) |
| "28), indicating a dose-response relationship." | 2.61 | Pregabalin add-on for drug-resistant focal epilepsy. ( Bresnahan, R; Hemming, K; Marson, AG; Panebianco, M, 2019) |
| "A generalized tonic-clonic seizure (GTCS) is the most severe form of common epileptic seizure and carries the greatest risk of harm." | 2.58 | Antiepileptic drug treatment of generalized tonic-clonic seizures: An evaluation of regulatory data and five criteria for drug selection. ( Bermejo, PE; Gibbs, AA; Huberfeld, G; Kälviäinen, R; Shorvon, SD, 2018) |
| "The aim of this review was to evaluate current literature for dosing recommendations for the use of antiepileptic medications in patients receiving renal replacement therapy (RRT)." | 2.53 | Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. ( Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016) |
| "In most cases, either the seizure or the medications used to treat the seizure may contribute to cognitive and psychosocial difficulties of various degrees of severity." | 2.52 | Clinical Management of Seizures in Patients With Low-Grade Glioma. ( Blakeley, J; Piotrowski, AF, 2015) |
| "Occurrence of generalized tonic-clonic seizures (GTCS) is one of the most important risk factors of seizure-related complications and comorbidities in patients with epilepsy." | 2.50 | Pharmacotherapy for tonic-clonic seizures. ( Rheims, S; Ryvlin, P, 2014) |
| "Epilepsy is one of the most common neurological conditions in the elderly, and the incidence of de novo geriatric epilepsy is rising." | 2.49 | [Epilepsy in the elderly]. ( Lossius, MI; Markhus, R; Nakken, KO; Sætre, E, 2013) |
| "Seizures and intracranial hemorrhage are possible medical diseases that any obstetrician may encounter." | 2.49 | Seizures and intracranial hemorrhage. ( Alexander, JM; Wilson, KL, 2013) |
| " It is well absorbed from the digestive system and undergoes metabolism via glucuronidation and acetylation." | 2.49 | [Retigabine - a new antiepileptic drug with a different mechanism of action]. ( Pietrzak, B; Zwierzyńska, E, 2013) |
| "There are no concerns regarding the treatment of seizures or increased pregnancy risk with the use of OCs and these non-enzyme-inducing AEDs." | 2.43 | Optimizing therapy of seizures in women who use oral contraceptives. ( Harden, CL; Leppik, I, 2006) |
| "Lamotrigine is a novel anticonvulsant, which has proven to be effective both as add-on and monotherapy." | 2.41 | The tolerability of lamotrigine in children. ( Giorgi, L; Messenheimer, JA; Risner, ME, 2000) |
| " In addition, fewer than half the number of patients in monotherapy studies who were taking lamotrigine discontinued treatment because of adverse events compared to those taking carbamazepine and phenytoin." | 2.40 | Safety review of adult clinical trial experience with lamotrigine. ( Giorgi, L; Messenheimer, J; Mullens, EL; Young, F, 1998) |
| "Forty patients (39." | 1.91 | Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. ( Barambio, S; Becerra, JL; Chíes, E; Ciurans, J; Codina, M; Fumanal, A; García-Esperón, C; Grau-López, L; Jiménez, M, 2023) |
| "We investigated the impact of repeated seizures on hippocampal memory and amyloid-β (Aβ) load in pre-symptomatic Tg2576 mice, a transgenic model of AD." | 1.91 | Lamotrigine rescues neuronal alterations and prevents seizure-induced memory decline in an Alzheimer's disease mouse model. ( Curia, G; Giorgi, C; Malerba, F; Marchetti, C; Merenda, E; Middei, S; Paolantoni, C; Pignataro, A; Pimpinella, D; Porcheddu, GF; Rizzello, E; Saviana, M; Titta, G, 2023) |
| "Seizures were classified into two categories: tonic‒clonic/focal to bilateral tonic‒clonic seizures and non-tonic‒clonic seizures." | 1.91 | Changes in seizure frequency and anti-seizure medication therapy during pregnancy and one year postpregnancy. ( Du, Y; Fang, W; Gong, J; Huang, W; Wang, X; Xia, N; Xu, H; Xu, Q; Zheng, R; Zhu, Z, 2023) |
| "There was consensus that seizures typically persist into adulthood, with remission occurring in <50% of patients." | 1.91 | Management of epilepsy with eyelid myoclonia: Results of an international expert consensus panel. ( Andrade, DM; Choi, H; Jones, H; Knupp, KG; Mugar, J; Nordli, DR; Riva, A; Smith, KM; Stern, JM; Striano, P; Thiele, EA; Trenité, DK; Wirrell, EC; Zawar, I, 2023) |
| "Temporal lobe epilepsy is a common, chronic disorder with spontaneous seizures that is often refractory to drug therapy." | 1.91 | Antiepileptogenic Effects of Anakinra, Lamotrigine and Their Combination in a Lithium-Pilocarpine Model of Temporal Lobe Epilepsy in Rats. ( Diespirov, GP; Griflyuk, AV; Kalita, AD; Postnikova, TY; Sinyak, DS; Zaitsev, AV; Zubareva, OE, 2023) |
| "All patients with a diagnosis of IGE, focal epilepsy, or SGE, who received either LTG or LEV, were recruited at the outpatient epilepsy clinic at Shiraz University of Medical Sciences, Shiraz, Iran from 2008 until 2020." | 1.72 | Rational therapy with lamotrigine or levetiracetam: Which one to select? ( Asadi-Pooya, AA; Farazdaghi, M, 2022) |
| "This study aimed to evaluate antiseizure medication (ASM) use in patients with JME." | 1.72 | Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020. ( Aydın, K; Cansu, A; Esenülkü, G; Haspolat, Ş; İnce, T; Kılıç, B; Okuyaz, Ç; Polat, BG; Serdaroğlu, A; Serdaroğlu, E; Tekgül, H; Topçu, Y, 2022) |
| "There have been several reports that switching formulations of antiseizure medications (ASMs) has been associated with a deterioration of seizure control, seizure relapse or increased adverse effects." | 1.72 | Analyzing excipient-related adverse events in antiseizure drug formulations. ( Ionova, Y; Peterson, T; Wilson, L, 2022) |
| "Epileptic spikes and seizures seem present early in the disease process of Alzheimer's disease (AD)." | 1.72 | Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease. ( Aourz, N; Barker-Haliski, M; Bjerke, M; De Bundel, D; Engelborghs, S; Nagels, G; Smolders, I; Vande Vyver, M, 2022) |
| "Specific antiseizure medications (ASM) would improve the outcome in post-stroke epilepsy (PSE)." | 1.72 | Efficacy and safety of antiseizure medication in post-stroke epilepsy. ( Groppa, S; Klimpe, S; Sandner, K; Stuckrad-Barre, SV; Uphaus, T; Winter, Y, 2022) |
| "Evidence for treating seizures in AS mainly derives from low-quality studies." | 1.72 | Pharmacotherapeutic management of seizures in patients with Angleman Syndrome. ( Samanta, D, 2022) |
| "Under lamotrigine, seizure aggravation was observed in 15 patients (two patients during levetiracetam, one patient during zonisamide, none during phenobarbital and valproic acid)." | 1.62 | Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy. ( Beier, CP; Gesche, J; Hjalgrim, H; Rubboli, G, 2021) |
| "Epilepsy was diagnosed in 54." | 1.62 | The molecular and phenotypic spectrum of CLCN4-related epilepsy. ( Cao, D; Fahlke, C; Guzman, RE; He, H; Peng, J; Sierra-Marquez, J; Stauber, T; Yin, F, 2021) |
| "Rats receiving LTG-BF1 recorded reduced seizure scores at all stages, longer latency time, and higher threshold PTZ dose compared to PTZ and market product groups." | 1.62 | Micellar buccal film for safe and effective control of seizures: Preparation, in vitro characterization, ex vivo permeation studies and in vivo assessment. ( Basha, M; Salama, AAA; Salama, AH, 2021) |
| "Carbamazepine was ineffective, and seizures were exacerbated with levetiracetam (LEV)." | 1.56 | Improvement of epilepsy with lacosamide in a patient with ring chromosome 20 syndrome. ( Goji, A; Kagami, S; Mori, T; Tayama, T; Toda, Y, 2020) |
| " Both, the type I isobolographic analysis and the test of parallelism of dose-response effects of the ASDs were used so as to properly classify interaction among three ASDs, administered in a fixed ratio combination of 1:1:1." | 1.56 | Sub-additive (antagonistic) interaction of lacosamide with lamotrigine and valproate in the maximal electroshock-induced seizure model in mice: an isobolographic analysis. ( Bojar, H; Florek-Łuszczki, M; Karwan, S; Kondrat-Wróbel, M; Plewa, Z; Zagaja, M; Łuszczki, JJ, 2020) |
| "Levetiracetam has replaced sodium valproate as the most frequently prescribed ASM in pediatric patients." | 1.56 | Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018. ( Dai, H; Feng, J; Yu, L; Yu, Z, 2020) |
| "Epilepsy is the disease associated with seizures and convulsions." | 1.56 | In-silico computational analysis of [6-(2, 3-Dichlorophenyl)-1, 2, 4-Triazine-3, 5-Diamine] metal complexes on voltage gated sodium channel and dihydrofolate reductase enzyme. ( Anwar, F; Arshad, S; Khan, MM; Najm, S; Naureen, H; Rehman, S; Sultana, K, 2020) |
| "Valproic acid was less frequently prescribed to female patients." | 1.56 | Observational multicentre study into the use of antiepileptic drugs in Spanish neurology consultations. ( Campos Blanco, DM; Castro Vilanova, MD; López Gonzalez, FJ; Mercadé Cerdá, JM; Querol Pascual, MR; Serrano Castro, P, 2020) |
| "Epileptic seizures were primary tonic-clonic (67." | 1.51 | Accidental injuries in patients with generalized tonic-clonic seizures. A multicenter, observational, cross-sectional study (QUIN-GTC study). ( Abraira, L; Iniesta, M; Puig, J; Salas-Puig, X, 2019) |
| "Then, spontaneous recurrent seizures (SRS), neuronal loss and astrogliosis were assessed." | 1.51 | The effects of lamotrigine and ethosuximide on seizure frequency, neuronal loss, and astrogliosis in a model of temporal-lobe epilepsy. ( Chen, Y; Sun, M; van Luijtelaar, G; Wang, J; Wang, Q, 2019) |
| "Patients with juvenile myoclonic epilepsy (JME) may have uncontrolled seizures." | 1.51 | Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy. ( Baftiu, A; Enger, U; Fløgstad, I; Johannessen Landmark, C; Johannessen, SI; Koht, J; Syvertsen, M, 2019) |
| "However, seizures are not typical and the majority of them were seizure-free." | 1.51 | A 16q22.2-q23.1 deletion identified in a male infant with West syndrome. ( Goji, A; Imoto, I; Ito, H; Kagami, S; Kohmoto, T; Mori, K; Mori, T; Toda, Y, 2019) |
| "Seizures are present in over 90% of infants and children with Wolf-Hirschhorn syndrome (WHS)." | 1.48 | A survey of antiepileptic drug responses identifies drugs with potential efficacy for seizure control in Wolf-Hirschhorn syndrome. ( Battaglia, A; Carey, JC; Ho, KS; Lortz, A; Markham, LM; Newcomb, T; Olson, LM; Sheng, X; Twede, H; Wassman, ER; Weng, C, 2018) |
| "Epilepsy is a serious neurological disease affecting about 1% of people worldwide (65 million)." | 1.48 | Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in a mouse tonic-clonic seizure model. ( Kondrat-Wróbel, MW; Łuszczki, JJ, 2018) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 1.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "Decrease of both the frequency of seizures and the incidence of ADRs after TDM implementation suggests that TDM may have given clinicians the opportunity to achieve more optimal patient treatment." | 1.46 | Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients. ( Brozmanova, H; Grundmann, M; Kacirova, I; Koristkova, B, 2017) |
| "The number of seizure-free patients in the last 4 weeks was overall CBZ/VPA/LTG/LEV=60%/79%/67%/67%, for generalized epilepsy was CBZ/VPA/LTG/LEV=67%/89%/65%/94%, and for localization-related epilepsy was CBZ/VPA/LTG/LEV=59%/71%/67%/57%." | 1.46 | Efficacy and tolerability of anti-epileptic drugs-an internet study. ( Baker, G; Wieshmann, UC, 2017) |
| " In another independent set of experiments, similar results of drug combination responses were also found." | 1.46 | Anti-Epileptic Drug Combination Efficacy in an In Vitro Seizure Model - Phenytoin and Valproate, Lamotrigine and Valproate. ( French, CR; O'Brien, TJ; Taing, KD; Williams, DA, 2017) |
| "Treatment with lamotrigine improved the patient's condition." | 1.43 | [Psychogenic non-epileptic seizures: issues of comorbidity in the diagnosis and treatment]. ( Nikolaev, EL; Rezvy, G; SÖrlie, T, 2016) |
| "Response to AED and change in seizure frequency/pattern on follow-up were noted." | 1.43 | Epilepsy with myoclonic absences: Electroclinical characteristics in a distinctive pediatric epilepsy phenotype. ( Jagtap, S; Karkare, K; Menon, RN; Radhakrishnan, A; Soni, H; Zanzmera, P, 2016) |
| "Adult patients with focal epilepsy, who were prescribed with carbamazepine (CBZ), valproate (VPA), lamotrigine (LTG), topiramate (TPM), or oxcarbazepine (OXC) as monotherapy, during the period from January 2004 to June 2012 registered in Wenzhou Epilepsy Follow Up Registry Database (WEFURD), were included in the study." | 1.42 | Comparative Long-Term Effectiveness of a Monotherapy with Five Antiepileptic Drugs for Focal Epilepsy in Adult Patients: A Prospective Cohort Study. ( Bao, YX; Fan, TT; He, RQ; Xu, HQ; Zeng, QY; Zheng, RY; Zhu, P, 2015) |
| "Lamotrigine treatment during KD is associated with a decreased efficacy of the KD." | 1.42 | Concomitant lamotrigine use is associated with decreased efficacy of the ketogenic diet in childhood refractory epilepsy. ( Catsman-Berrevoets, CE; Desadien, R; Neuteboom, RF; van der Louw, EJ; van der Sijs, H; Vehmeijer, FO, 2015) |
| " The data collected included epilepsy type, seizure frequency, concomitant anti-epileptic drugs, dosage of LTG and LTG serum levels." | 1.40 | [Clinical efficacy and pharmacokinetics of lamotrigine for childhood-onset intractable epilepsy]. ( Arakawa, C; Endo, A; Fuchigami, T; Fujita, Y; Imai, Y; Ishii, W; Kohira, R; Momoki, E; Mugishima, H, 2014) |
| "Immediate release lamotrigine (LTG-IR) dosing can be limited by peak toxicity." | 1.40 | Conversion from immediate-release to extended-release lamotrigine improves seizure control. ( Abou-Khalil, B; Osborn, M; Ramey, P, 2014) |
| "Lamotrigine (LTG) is a popular modern antiepileptic drug (AED); however, its mechanism of action has yet to be fully understood, as it is known to modulate many members of several ion channel families." | 1.39 | Cav 2.3 (R-type) calcium channels are critical for mediating anticonvulsive and neuroprotective properties of lamotrigine in vivo. ( Alpdogan, S; Dibué, M; Hescheler, J; Kamp, MA; Neiss, WF; Schneider, T; Tevoufouet, EE, 2013) |
| "Lamotrigine is a phenyltriazine compound that inhibits voltage-gated sodium channels, decreasing release of glutamate and aspartate, and inhibits serotonin, norepinephrine and dopamine reuptake." | 1.39 | A case series of patients with lamotrigine toxicity at one center from 2003 to 2012. ( Burkhart, KK; Donovan, JW; Haggerty, D; Moore, PW, 2013) |
| "Tonic hind limb extension (seizure activity) was evoked in adult male albino Swiss mice by a current (sine-wave, 25 mA, 500 V, 50 Hz, 0." | 1.39 | Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Florek-Luszczki, M; Karwan, S; Luszczki, JJ; Wlaz, A, 2013) |
| "In reflex seizures induced by proprioceptive stimuli, the activated network may be identified as a single anatomo-functional circuit; the sensory-motor network." | 1.38 | Are proprioceptive-induced reflex seizures epileptically-enhanced stretch reflex manifestations? ( Arányi, Z; Erőss, L; Holló, A; Janszky, J; Kamondi, A; Orbay, P; Rásonyi, G; Sólyom, A; Szűcs, A, 2012) |
| "It also proved protection in focal seizures (electric kindling, rats, ip) and it raises seizure threshold." | 1.37 | Synthesis and anticonvulsant activity of trans- and cis-2-(2,6-dimethylphenoxy)-N-(2- or 4-hydroxycyclohexyl)acetamides and their amine analogs. ( Marona, H; Pękala, E; Szneler, E; Walczak, M; Waszkielewicz, AM, 2011) |
| " Chronic administration of bupropion significantly potentiates the protective activity of lamotrigine, topiramate, and felbamate against maximal electroshock-induced seizures." | 1.37 | Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. ( Bańka, K; Barczyński, B; Buszewicz, G; Mądro, R; Mróz, T; Tutaj, K; Tutka, P; Wielosz, M; Łuszczki, JJ, 2011) |
| "JME patients without generalized tonic clonic seizures (GTCS) responded better to LTG (P = 0." | 1.37 | Outcome of lamotrigine treatment in juvenile myoclonic epilepsy. ( Ben-Zeev, B; Blatt, I; Bodenstein-Sachar, H; Chapman, J; Gandelman-Marton, R, 2011) |
| " To conclude, long term administration of topiramate impairs cognitive functions during experimental epilepsy while lamotrigine and oxcarbazepine are safer." | 1.37 | Effect of lamotrigine, oxcarbazepine and topiramate on cognitive functions and oxidative stress in PTZ-kindled mice. ( Agarwal, NB; Agarwal, NK; Mediratta, PK; Sharma, KK, 2011) |
| "On VPA 1000 mg/d, the seizure frequency decreased significantly." | 1.37 | Valproate treatment after liver transplant in a patient with Lennox-Gastaut syndrome. ( Crespel, A; Gelisse, P; Genton, P; Pageaux, GP; Velizarova, R, 2011) |
| "Causes of brain abscesses are multiple and often unclear." | 1.37 | Cerebral abscess due to an abnormal drainage of the superior vena cava. ( Alamowitch, S; Hammoudi, N; Khalil, A; Muresan, IP; Yger, M, 2011) |
| "An epileptic seizure is reported in a 38-year-old woman, known to be an epileptic patient." | 1.37 | Epileptic seizure induced by fennel essential oil. ( Skalli, S; Soulaymani Bencheikh, R, 2011) |
| "Falling due to startle-induced seizures (SISs) often leads to injury." | 1.37 | Lamotrigine is favourable for startle-induced seizures. ( Fujiwara, T; Ikeda, H; Imai, K; Inoue, Y; Shigematsu, H; Shishido, T; Takahashi, Y; Takayama, R, 2011) |
| "Lamotrigine treatment had no effect on oxidative stress parameters alone, while it significantly decreased oxidative stress in the pentylenetetrazole-kindled group as compared to the pentylenetetrazole-kindled carbamazepine-treated group." | 1.36 | Effect of carbamazepine and lamotrigine on cognitive function and oxidative stress in brain during chemical epileptogenesis in rats. ( Arora, T; Banerjee, BD; Garg, GR; Mediratta, PK; Mehta, AK; Sharma, AK; Sharma, KK, 2010) |
| "The aim of this study was to characterize the anticonvulsant effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline (MeTHIQ--an endogenous parkinsonism-preventing substance) in combination with four second-generation antiepileptic drugs (AEDs: lamotrigine [LTG], oxcarbazepine [OXC], pregabalin [PGB], and topiramate [TPM]) in the mouse maximal electroshock (MES)-induced seizure model by using the type I isobolographic analysis for parallel and non-parallel dose-response relationship curves (DRRCs)." | 1.36 | Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis. ( Antkiewicz-Michaluk, L; Czuczwar, SJ; Luszczki, JJ; Raszewski, G, 2010) |
| ", lamotrigine [LTG], oxcarbazepine [OXC] and topiramate [TPM]) in the mouse maximal electroshock (MES)-induced seizure model by using the type I isobolographic analysis for non-parallel dose-response relationship curves (DRRCs)." | 1.36 | Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. ( Czuczwar, SJ; Filip, D; Luszczki, JJ, 2010) |
| "A 41-year-old Caucasian female with MELAS syndrome, presenting with short stature, microcytic anaemia, increased blood-sedimentation rate, myopathy, hyper-gammaglobulinaemia, an iron-metabolism defect, migraine-like headaches, and stroke-like episodes, developed complex partial and generalised seizures at age 32 years." | 1.36 | Regression of stroke-like lesions in MELAS-syndrome after seizure control. ( Barton, P; Finsterer, J, 2010) |
| " The isobolographic analysis for parallel and nonparallel dose-response effects was used in the mouse maximal electroshock seizure (MES) model for evaluation of pharmacodynamic interaction." | 1.35 | Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. ( Czuczwar, SJ; Luszczki, JJ; Raszewski, G; Wu, JZ, 2009) |
| "Efficacy of seizure control was considered satisfactory if there was a reduction in seizures>50% or total control." | 1.35 | Association of lamotrigine and valproate in refractory epilepsies of children and adolescents. ( Antoniuk, SA; Bruck, I; Grisotto, KP; Santos, LH, 2008) |
| "Lamotrigine (LTG) is an antiepileptic drug, a glutamate release inhibitor, with action at the neuronal voltage-gated sodium channel." | 1.35 | NA+, K+-ATPase activity in the brain of the rats with kainic acid-induced seizures: influence of lamotrigine. ( Ljubicić, D; Pelcić, JM; Simonić, A; Vitezić, D; Vitezić, M; Zupan, G, 2008) |
| "We believe that the neonatal seizures were caused by lamotrigin withdrawal." | 1.35 | [Neonatal seizures caused by lamotrigin withdrawal?]. ( Längler, A; Thiel, M; Vieker, S, 2009) |
| "Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited." | 1.35 | Efficacy of anti-epileptic drugs in patients with gliomas and seizures. ( Rijsman, RM; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2009) |
| " Chronic administration of ETA (12." | 1.35 | Effect of ethacrynic acid on the anticonvulsant activity of the second-generation antiepileptics against maximal electroshock-induced seizures in mice. ( Czuczwar, SJ; Swiderska, G; Łukawski, K, 2009) |
| "The significant proportion of seizure-free cases (27%) on duotherapy is suggesting the usefulness of combination therapy in achieving seizure-freedom in epilepsies refractory to single drug treatment." | 1.35 | Seizure-freedom with combination therapy in localization-related epilepsy. ( Auvinen, A; Keränen, T; Kharazmi, E; Peltola, J; Peltola, M; Raitanen, J, 2008) |
| " The manufacturer recommends half the dosage of lamotrigine monotherapy when the patient also uses valproate." | 1.35 | Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. ( Aldenkamp, AP; Bootsma, HP; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Savelkoul, M; Schellekens, A; Vos, AM, 2008) |
| "The patient presented with seizures and a reduced level of consciousness." | 1.34 | Self-poisoning with lamotrigine and pregabalin. ( Braga, AJ; Chidley, K, 2007) |
| "Lamotrigine is a commonly prescribed anticonvulsant medication." | 1.34 | Seizures and altered mental status after lamotrigine overdose. ( Geller, RJ; Schwartz, MD, 2007) |
| " However, these combinations were associated with significant pharmacokinetic interactions, in that LCZ increased brain TPM (94%), OXC (21%), FBM (46%), and LTG (8%) concentrations." | 1.33 | Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model. ( Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2005) |
| "LTG in some regions of the CNS enhanced seizure-induced IEG expression." | 1.33 | Valproic acid, but not lamotrigine, suppresses seizure-induced c-fos and c-Jun mRNA expression. ( Anderson, GD; Shen, DD; Szot, P; White, SS, 2005) |
| "Lamotrigine (LTG) was prescribed in 29 patients as add-on therapy." | 1.33 | The use of lamotrigine and other antiepileptic drugs in paediatric patients at a Malaysian hospital. ( Ab Rahman, AF; Ibrahim, MI; Ismail, HI; Seng, TB, 2005) |
| " This study was designed to assess the antiepileptic activity of aspirin and to investigate the potentiation of its activity in combination with a subconvulsive dose of lamotrigine." | 1.32 | Evaluation of antiepileptic activity of aspirin in combination with newer antiepileptic lamotrigine in mice. ( Anuradha, K; Pandhi, P; Tandon, M, 2003) |
| "The pharmacodynamic interaction between the antiepileptic drugs (AEDs) tiagabine (TGB) and lamotrigine (LTG) was characterized on basis of the anticonvulsant effect in the cortical stimulation model in the rat." | 1.32 | Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat. ( Danhof, M; Jonker, DM; Voskuyl, RA, 2004) |
| "Using an amygdala-kindled seizure paradigm, we evaluated the acute and chronic anticonvulsant effects of lamotrigine (LTG)." | 1.31 | Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: cross-tolerance to carbamazepine but not valproate or diazepam. ( Heynen, T; Krupp, E; Li, XL; Post, RM; Weiss, SR, 2000) |
| "Lamotrigine (LTG) is an anticonvulsant that is currently in use for the treatment of various seizure disorders and that shows promise in the treatment of affective illness." | 1.31 | Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy. ( Krupp, E; Li, XL; Post, RM; Postma, T; Weiss, SR, 2000) |
| "Lamotrigine (LTG) is an antiepileptic drug that is also effective in the treatment of certain psychiatric disorders." | 1.31 | Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders. ( Aroniadou-Anderjaska, V; Braga, MF; Li, H; Post, RM, 2002) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 1.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "The anti-seizure activity of DCG-IV was fully inhibited in the presence of the group II metabotropic glutamate receptor antagonist (2S,1'S, 2'S)-2-methyl-2-(carboxycyclopropyl)glycine (MCCG; 40 nmol), while MCCG alone showed no significant inhibitory effect on seizure activity." | 1.30 | Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV). ( Attwell, PJ; Bradford, HF; Croucher, MJ; Jane, DE; Singh Kent, N, 1998) |
| "A newborn infant with seizures of unknown etiology that were refractory to treatment with phenobarbitone, phenytoin, midazolam, clonazepam, and vigabatrin is reported." | 1.30 | Efficacy of lamotrigine in refractory neonatal seizures. ( Antony, JH; Barr, PA; Buettiker, VE, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.40) | 18.7374 |
| 1990's | 31 (12.55) | 18.2507 |
| 2000's | 67 (27.13) | 29.6817 |
| 2010's | 92 (37.25) | 24.3611 |
| 2020's | 56 (22.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pevarello, P | 1 |
| Bonsignori, A | 1 |
| Dostert, P | 1 |
| Heidempergher, F | 1 |
| Pinciroli, V | 1 |
| Colombo, M | 1 |
| McArthur, RA | 1 |
| Salvati, P | 1 |
| Post, C | 1 |
| Fariello, RG | 1 |
| Varasi, M | 1 |
| Maillard, MC | 1 |
| Perlman, ME | 1 |
| Amitay, O | 1 |
| Baxter, D | 1 |
| Berlove, D | 1 |
| Connaughton, S | 1 |
| Fischer, JB | 1 |
| Guo, JQ | 1 |
| Hu, LY | 1 |
| McBurney, RN | 1 |
| Nagy, PI | 1 |
| Subbarao, K | 1 |
| Yost, EA | 1 |
| Zhang, L | 1 |
| Durant, GJ | 1 |
| Pękala, E | 1 |
| Waszkielewicz, AM | 1 |
| Szneler, E | 1 |
| Walczak, M | 1 |
| Marona, H | 1 |
| Kuder, K | 1 |
| Łażewska, D | 1 |
| Latacz, G | 1 |
| Schwed, JS | 1 |
| Karcz, T | 1 |
| Stark, H | 1 |
| Karolak-Wojciechowska, J | 1 |
| Kieć-Kononowicz, K | 1 |
| Müffelmann, B | 1 |
| Hagemann, A | 1 |
| Knaak, N | 1 |
| Bien, CG | 1 |
| Chalasani, N | 1 |
| Bonkovsky, HL | 1 |
| Stine, JG | 1 |
| Gu, J | 1 |
| Barnhart, H | 1 |
| Jacobsen, E | 1 |
| Björnsson, E | 1 |
| Fontana, RJ | 1 |
| Kleiner, DE | 1 |
| Hoofnagle, JH | 1 |
| Hotta, N | 1 |
| Miyamoto, M | 1 |
| Suzuki, K | 1 |
| Asadi-Pooya, AA | 1 |
| Farazdaghi, M | 1 |
| Elmer, S | 1 |
| Reddy, DS | 1 |
| Ryvlin, P | 3 |
| Dimova, S | 1 |
| Elmoufti, S | 2 |
| Floricel, F | 1 |
| Laloyaux, C | 1 |
| Nondonfaz, X | 1 |
| Biton, V | 3 |
| Kılıç, B | 1 |
| Serdaroğlu, E | 1 |
| Polat, BG | 1 |
| İnce, T | 1 |
| Esenülkü, G | 1 |
| Topçu, Y | 1 |
| Serdaroğlu, A | 1 |
| Haspolat, Ş | 1 |
| Tekgül, H | 1 |
| Okuyaz, Ç | 1 |
| Cansu, A | 1 |
| Aydın, K | 1 |
| Ionova, Y | 1 |
| Peterson, T | 1 |
| Wilson, L | 1 |
| Mehrotra, S | 1 |
| Bhattaram, A | 1 |
| Krudys, K | 1 |
| Bewernitz, M | 1 |
| Uppoor, R | 1 |
| Mehta, M | 1 |
| Liu, T | 1 |
| Sheridan, P | 1 |
| Hershkowitz, N | 1 |
| Kozauer, N | 1 |
| Bastings, E | 1 |
| Dunn, B | 1 |
| Men, AY | 1 |
| Vande Vyver, M | 1 |
| Barker-Haliski, M | 2 |
| Aourz, N | 1 |
| Nagels, G | 1 |
| Bjerke, M | 1 |
| Engelborghs, S | 1 |
| De Bundel, D | 1 |
| Smolders, I | 2 |
| Chen, Y | 3 |
| Chen, J | 2 |
| Zhuang, X | 1 |
| Chen, X | 1 |
| Zeng, J | 1 |
| Wang, R | 1 |
| Miao, J | 1 |
| Winter, Y | 1 |
| Uphaus, T | 1 |
| Sandner, K | 1 |
| Klimpe, S | 1 |
| Stuckrad-Barre, SV | 1 |
| Groppa, S | 1 |
| Panda, SP | 1 |
| Dhurandhar, Y | 1 |
| Agrawal, M | 1 |
| Samanta, D | 1 |
| Merseburg, A | 1 |
| Kasemir, J | 1 |
| Buss, EW | 1 |
| Leroy, F | 1 |
| Bock, T | 1 |
| Porro, A | 1 |
| Barnett, A | 1 |
| Tröder, SE | 1 |
| Engeland, B | 1 |
| Stockebrand, M | 1 |
| Moroni, A | 1 |
| Siegelbaum, SA | 1 |
| Isbrandt, D | 1 |
| Santoro, B | 1 |
| Jiménez, M | 1 |
| Grau-López, L | 1 |
| Ciurans, J | 1 |
| García-Esperón, C | 1 |
| Fumanal, A | 1 |
| Barambio, S | 1 |
| Chíes, E | 1 |
| Codina, M | 1 |
| Becerra, JL | 1 |
| Bleakley, LE | 1 |
| McKenzie, CE | 1 |
| Reid, CA | 1 |
| Aboumatar, S | 1 |
| Krishnaiengar, SR | 1 |
| Cantu, D | 2 |
| Zhang, Y | 2 |
| Grinnell, T | 3 |
| Chmielewska, N | 1 |
| Wawer, A | 1 |
| Wicik, Z | 1 |
| Osuch, B | 1 |
| Maciejak, P | 1 |
| Szyndler, J | 1 |
| Rizzello, E | 1 |
| Pimpinella, D | 1 |
| Pignataro, A | 1 |
| Titta, G | 1 |
| Merenda, E | 1 |
| Saviana, M | 1 |
| Porcheddu, GF | 1 |
| Paolantoni, C | 1 |
| Malerba, F | 1 |
| Giorgi, C | 1 |
| Curia, G | 1 |
| Middei, S | 1 |
| Marchetti, C | 1 |
| Jin, K | 1 |
| Harby, SA | 1 |
| Khalil, NA | 1 |
| El-Sayed, NS | 1 |
| Thabet, EH | 1 |
| Saleh, SR | 1 |
| Fathelbab, MH | 1 |
| Du, Y | 1 |
| Fang, W | 1 |
| Huang, W | 1 |
| Xu, Q | 1 |
| Gong, J | 1 |
| Xia, N | 1 |
| Zhu, Z | 1 |
| Wang, X | 1 |
| Zheng, R | 1 |
| Xu, H | 1 |
| Smith, KM | 1 |
| Wirrell, EC | 1 |
| Andrade, DM | 2 |
| Choi, H | 1 |
| Trenité, DK | 1 |
| Jones, H | 1 |
| Knupp, KG | 1 |
| Mugar, J | 1 |
| Nordli, DR | 1 |
| Riva, A | 1 |
| Stern, JM | 1 |
| Striano, P | 1 |
| Thiele, EA | 1 |
| Zawar, I | 1 |
| Ziganshina, LE | 1 |
| Abakumova, T | 1 |
| Hoyle, CHV | 1 |
| Barry, JM | 1 |
| French, JA | 2 |
| Pennell, PB | 1 |
| Karanam, A | 1 |
| Harden, CL | 3 |
| Birnbaum, AK | 1 |
| Vajda, F | 2 |
| O'Brien, T | 2 |
| Graham, J | 2 |
| Hitchcock, A | 1 |
| Perucca, P | 1 |
| Lander, C | 2 |
| Eadie, M | 2 |
| Zubareva, OE | 1 |
| Sinyak, DS | 1 |
| Kalita, AD | 1 |
| Griflyuk, AV | 1 |
| Diespirov, GP | 1 |
| Postnikova, TY | 1 |
| Zaitsev, AV | 1 |
| Boutet, A | 1 |
| Jain, M | 1 |
| Elias, GJB | 1 |
| Gramer, R | 1 |
| Germann, J | 1 |
| Davidson, B | 1 |
| Coblentz, A | 1 |
| Giacobbe, P | 1 |
| Kucharczyk, W | 1 |
| Wennberg, RA | 1 |
| Ibrahim, GM | 1 |
| Lozano, AM | 1 |
| Cao, J | 1 |
| Lin, XX | 1 |
| Ma, XM | 1 |
| Liu, H | 1 |
| Kuczynska, J | 1 |
| Karas-Ruszczyk, K | 1 |
| Zakrzewska, A | 1 |
| Dermanowski, M | 1 |
| Sienkiewicz-Jarosz, H | 1 |
| Kurkowska-Jastrzebska, I | 1 |
| Bienkowski, P | 1 |
| Konopko, M | 1 |
| Dominiak, M | 1 |
| Mierzejewski, P | 1 |
| Keni, RR | 1 |
| Jose, M | 1 |
| A S, R | 1 |
| Baishya, J | 1 |
| Sankara Sarma, P | 1 |
| Thomas, SV | 1 |
| Eksambe, P | 1 |
| Shah, YD | 1 |
| Edelstein, A | 1 |
| Kothare, S | 1 |
| Sanchez, DL | 1 |
| Fusick, AJ | 1 |
| Gunther, SR | 1 |
| Hernandez, MJ | 1 |
| Sullivan, GA | 1 |
| Catalano, MC | 1 |
| Catalano, G | 1 |
| Ruan, Y | 1 |
| Xu, C | 1 |
| Lan, J | 1 |
| Nao, J | 1 |
| Zhang, S | 2 |
| Fan, F | 1 |
| Wang, Y | 2 |
| Chen, Z | 1 |
| Panebianco, M | 2 |
| Bresnahan, R | 2 |
| Ramaratnam, S | 1 |
| Marson, AG | 5 |
| Tayama, T | 1 |
| Mori, T | 2 |
| Goji, A | 2 |
| Toda, Y | 2 |
| Kagami, S | 2 |
| Łuszczki, JJ | 6 |
| Kondrat-Wróbel, M | 1 |
| Zagaja, M | 2 |
| Karwan, S | 3 |
| Bojar, H | 2 |
| Plewa, Z | 2 |
| Florek-Łuszczki, M | 4 |
| Jung, I | 1 |
| Shin, JH | 1 |
| Kim, J | 1 |
| Koneval, Z | 1 |
| Knox, KM | 1 |
| Memon, A | 1 |
| Zierath, DK | 1 |
| White, HS | 2 |
| Yu, L | 1 |
| Feng, J | 1 |
| Yu, Z | 1 |
| Dai, H | 1 |
| Suleman, N | 1 |
| Ozdemirli, M | 1 |
| Weisman, D | 1 |
| Gesche, J | 1 |
| Hjalgrim, H | 1 |
| Rubboli, G | 1 |
| Beier, CP | 1 |
| Brigo, F | 2 |
| Igwe, SC | 1 |
| Lattanzi, S | 2 |
| Hixson, J | 1 |
| Gidal, B | 1 |
| Pikalov, A | 1 |
| Mehta, D | 1 |
| Blum, D | 2 |
| Najm, S | 1 |
| Naureen, H | 1 |
| Sultana, K | 1 |
| Anwar, F | 1 |
| Rehman, S | 1 |
| Arshad, S | 1 |
| Khan, MM | 1 |
| Müller, RM | 1 |
| Herziger, B | 1 |
| Jeschke, S | 1 |
| Neininger, MP | 1 |
| Bertsche, T | 1 |
| Bertsche, A | 1 |
| He, H | 1 |
| Guzman, RE | 1 |
| Cao, D | 1 |
| Sierra-Marquez, J | 1 |
| Yin, F | 1 |
| Fahlke, C | 1 |
| Peng, J | 1 |
| Stauber, T | 1 |
| Zaccara, G | 1 |
| Załuska-Ogryzek, K | 1 |
| Marzęda, P | 1 |
| Wróblewska-Łuczka, P | 2 |
| Zolkowska, D | 2 |
| van Opijnen, MP | 1 |
| van der Meer, PB | 1 |
| Dirven, L | 1 |
| Fiocco, M | 1 |
| Kouwenhoven, MCM | 1 |
| van den Bent, MJ | 1 |
| Taphoorn, MJB | 1 |
| Koekkoek, JAF | 1 |
| Smith, PEM | 1 |
| Pieróg, M | 1 |
| Socała, K | 2 |
| Doboszewska, U | 1 |
| Wyska, E | 2 |
| Guz, L | 1 |
| Szopa, A | 1 |
| Serefko, A | 1 |
| Poleszak, E | 1 |
| Wlaź, P | 2 |
| Nayak, SM | 1 |
| Gukasyan, N | 1 |
| Barrett, FS | 1 |
| Erowid, E | 1 |
| Erowid, F | 1 |
| Griffiths, RR | 1 |
| Li, J | 1 |
| Toffa, DH | 1 |
| Nguyen, DK | 2 |
| Salama, AH | 1 |
| Basha, M | 1 |
| Salama, AAA | 1 |
| Grundmann, M | 1 |
| Koristkova, B | 1 |
| Brozmanova, H | 1 |
| Kacirova, I | 1 |
| He, X | 1 |
| Sun, Q | 1 |
| Fang, Z | 1 |
| Zhou, L | 1 |
| Benbadis, S | 1 |
| Klein, P | 2 |
| Schiemann, J | 1 |
| Diaz, A | 1 |
| Whitesides, J | 1 |
| Ho, KS | 1 |
| Markham, LM | 1 |
| Twede, H | 1 |
| Lortz, A | 1 |
| Olson, LM | 1 |
| Sheng, X | 1 |
| Weng, C | 1 |
| Wassman, ER | 2 |
| Newcomb, T | 1 |
| Carey, JC | 1 |
| Battaglia, A | 1 |
| Mercadé Cerdá, JM | 1 |
| López Gonzalez, FJ | 1 |
| Serrano Castro, P | 1 |
| Castro Vilanova, MD | 1 |
| Campos Blanco, DM | 1 |
| Querol Pascual, MR | 1 |
| Rivero Rodríguez, D | 1 |
| Scherle Matamoros, C | 1 |
| Dicapua Sacoto, D | 1 |
| Maldonado Samaniego, N | 1 |
| Shorvon, SD | 1 |
| Bermejo, PE | 1 |
| Gibbs, AA | 1 |
| Huberfeld, G | 1 |
| Kälviäinen, R | 1 |
| Kondrat-Wróbel, MW | 2 |
| Thangaratinam, S | 1 |
| Marlin, N | 1 |
| Newton, S | 1 |
| Weckesser, A | 1 |
| Bagary, M | 1 |
| Greenhill, L | 1 |
| Rikunenko, R | 1 |
| D'Amico, M | 1 |
| Rogozińska, E | 1 |
| Kelso, A | 1 |
| Hard, K | 1 |
| Coleman, J | 1 |
| Moss, N | 1 |
| Roberts, T | 1 |
| Middleton, L | 1 |
| Dodds, J | 1 |
| Pullen, A | 1 |
| Eldridge, S | 1 |
| Pirie, A | 1 |
| Denny, E | 1 |
| McCorry, D | 1 |
| Khan, KS | 1 |
| Yasumoto, S | 1 |
| Ohtsuka, Y | 1 |
| Sato, K | 2 |
| Kurata, A | 1 |
| Numachi, Y | 1 |
| Shimizu, M | 1 |
| Abou-Khalil, B | 2 |
| Shah, A | 1 |
| Specchio, LM | 1 |
| Gama, H | 1 |
| Rocha, F | 1 |
| Cheng, H | 1 |
| Jung, J | 1 |
| Salas-Puig, X | 1 |
| Iniesta, M | 1 |
| Abraira, L | 1 |
| Puig, J | 1 |
| Wang, J | 1 |
| Wang, Q | 1 |
| van Luijtelaar, G | 1 |
| Sun, M | 1 |
| Kessler, SK | 1 |
| McGinnis, E | 1 |
| Sawicka, KM | 1 |
| Wawryniuk, A | 1 |
| Daniluk, J | 2 |
| Chmielewski, J | 1 |
| Ding, Y | 1 |
| Tan, X | 1 |
| Guo, Y | 1 |
| Hemming, K | 1 |
| Johannessen Landmark, C | 1 |
| Fløgstad, I | 1 |
| Syvertsen, M | 1 |
| Baftiu, A | 1 |
| Enger, U | 1 |
| Koht, J | 1 |
| Johannessen, SI | 1 |
| Ito, H | 1 |
| Mori, K | 1 |
| Kohmoto, T | 1 |
| Imoto, I | 1 |
| Szafarz, M | 1 |
| Nieoczym, D | 1 |
| Nakken, KO | 1 |
| Sætre, E | 1 |
| Markhus, R | 1 |
| Lossius, MI | 1 |
| Rezvy, G | 2 |
| Sørlie, T | 1 |
| Wilson, KL | 1 |
| Alexander, JM | 1 |
| Shneker, BF | 1 |
| Naritoku, D | 1 |
| Hammer, AE | 8 |
| Vuong, A | 6 |
| Caldwell, PT | 2 |
| Messenheimer, JA | 4 |
| Tutka, P | 2 |
| Mróz, T | 2 |
| Bednarski, J | 1 |
| Styk, A | 1 |
| Ognik, J | 1 |
| Mosiewicz, J | 1 |
| Łuszczki, J | 1 |
| Tayah, T | 1 |
| Savard, M | 1 |
| Desbiens, R | 1 |
| Belozertsev, IuA | 1 |
| Zapol'skaia, IuA | 1 |
| Belozertsev, FIu | 1 |
| Iuntsev, SV | 1 |
| Dibué, M | 1 |
| Kamp, MA | 1 |
| Alpdogan, S | 1 |
| Tevoufouet, EE | 1 |
| Neiss, WF | 1 |
| Hescheler, J | 1 |
| Schneider, T | 1 |
| Battino, D | 1 |
| Tomson, T | 1 |
| Bonizzoni, E | 1 |
| Craig, J | 1 |
| Lindhout, D | 1 |
| Sabers, A | 1 |
| Perucca, E | 2 |
| Moore, PW | 1 |
| Donovan, JW | 1 |
| Burkhart, KK | 1 |
| Haggerty, D | 1 |
| Pocsay, G | 1 |
| Gazdag, A | 1 |
| Engelhardt, J | 1 |
| Szaniszló, I | 1 |
| Szolnoki, Z | 1 |
| Forczek, G | 1 |
| Mikló, L | 1 |
| García, N | 1 |
| Aragonès, JM | 1 |
| Zwierzyńska, E | 1 |
| Pietrzak, B | 1 |
| Luszczki, JJ | 9 |
| Wlaz, A | 1 |
| Florek-Luszczki, M | 2 |
| Czuczwar, SJ | 10 |
| Bonnett, LJ | 1 |
| Tudur Smith, C | 1 |
| Smith, D | 1 |
| Williamson, PR | 2 |
| Chadwick, D | 1 |
| Ishii, W | 1 |
| Fujita, Y | 1 |
| Momoki, E | 1 |
| Imai, Y | 1 |
| Endo, A | 1 |
| Arakawa, C | 1 |
| Kohira, R | 1 |
| Fuchigami, T | 1 |
| Mugishima, H | 1 |
| Rheims, S | 1 |
| Wechsler, RT | 1 |
| Leroy, R | 1 |
| Van Cott, A | 1 |
| Huffman, R | 1 |
| VanLandingham, K | 1 |
| Aksoy, D | 1 |
| Cevik, B | 1 |
| Kurt, S | 1 |
| Pekdas, E | 1 |
| Solmaz, V | 1 |
| Vajda, FJ | 1 |
| Ramey, P | 1 |
| Osborn, M | 1 |
| Dalic, L | 1 |
| Mullen, SA | 1 |
| Roulet Perez, E | 1 |
| Scheffer, I | 1 |
| Shazadi, K | 1 |
| Petrovski, S | 1 |
| Roten, A | 1 |
| Miller, H | 1 |
| Huggins, RM | 1 |
| Brodie, MJ | 1 |
| Pirmohamed, M | 1 |
| Johnson, MR | 1 |
| O'Brien, TJ | 3 |
| Sills, GJ | 1 |
| Cao, Z | 1 |
| Zou, X | 1 |
| Cui, Y | 1 |
| Hulsizer, S | 1 |
| Lein, PJ | 1 |
| Wulff, H | 1 |
| Pessah, IN | 1 |
| Banach, M | 1 |
| Borowicz, KK | 1 |
| Gavzan, H | 1 |
| Sayyah, M | 1 |
| Sardari, S | 1 |
| Babapour, V | 1 |
| Piotrowski, AF | 1 |
| Blakeley, J | 1 |
| Zeng, QY | 1 |
| Fan, TT | 1 |
| Zhu, P | 1 |
| He, RQ | 1 |
| Bao, YX | 1 |
| Zheng, RY | 1 |
| Xu, HQ | 1 |
| Lerche, H | 1 |
| Lotay, N | 1 |
| DeRossett, S | 1 |
| Edwards, S | 1 |
| Brandt, C | 1 |
| van der Louw, EJ | 1 |
| Desadien, R | 1 |
| Vehmeijer, FO | 1 |
| van der Sijs, H | 1 |
| Catsman-Berrevoets, CE | 1 |
| Neuteboom, RF | 1 |
| Lee, SA | 1 |
| Kim, MJ | 1 |
| Lee, HW | 2 |
| Heo, K | 1 |
| Shin, DJ | 1 |
| Song, HK | 1 |
| Kim, OJ | 1 |
| Kim, SO | 1 |
| Lee, BI | 1 |
| Abou-Khalil, BW | 1 |
| Barrera-Bailón, B | 1 |
| Oliveira, JAC | 1 |
| López, DE | 1 |
| Muñoz, LJ | 1 |
| Garcia-Cairasco, N | 1 |
| Sancho, C | 1 |
| Krauß, M | 1 |
| Berkermann, H | 1 |
| Ghadimi, M | 1 |
| Gaedcke, J | 1 |
| Bürger, T | 1 |
| Nikolaev, EL | 1 |
| SÖrlie, T | 1 |
| Martinez Ferri, M | 1 |
| Peña Mayor, P | 1 |
| Perez López-Fraile, I | 1 |
| Escartin Siquier, A | 1 |
| Martin Moro, M | 1 |
| Forcadas Berdusan, M | 1 |
| Smetana, KS | 1 |
| Cook, AM | 1 |
| Bastin, ML | 1 |
| Oyler, DR | 1 |
| Andres-Mach, M | 1 |
| Patrzylas, P | 1 |
| Pyrka, D | 1 |
| Szpringer, M | 1 |
| Żółkowska, D | 1 |
| Skalicka-Woźniak, K | 1 |
| Wieshmann, UC | 1 |
| Baker, G | 1 |
| Zanzmera, P | 1 |
| Menon, RN | 1 |
| Karkare, K | 1 |
| Soni, H | 1 |
| Jagtap, S | 1 |
| Radhakrishnan, A | 1 |
| Taing, KD | 1 |
| Williams, DA | 1 |
| French, CR | 1 |
| Zelnik, N | 1 |
| Isler, N | 1 |
| Goez, H | 1 |
| Shiffer, M | 1 |
| David, M | 1 |
| Shahar, E | 1 |
| Valencia, I | 1 |
| Piñol-Ripoll, G | 1 |
| Khurana, DS | 1 |
| Hardison, HH | 1 |
| Kothare, SV | 1 |
| Melvin, JJ | 1 |
| Marks, HG | 1 |
| Legido, A | 1 |
| Bidlack, JM | 1 |
| Morris, HH | 1 |
| Wade, JF | 1 |
| Dang, CV | 1 |
| Nelson, L | 1 |
| Wasserberger, J | 1 |
| Wu, JZ | 1 |
| Raszewski, G | 2 |
| Grisotto, KP | 1 |
| Bruck, I | 1 |
| Antoniuk, SA | 1 |
| Santos, LH | 1 |
| Vitezić, D | 1 |
| Pelcić, JM | 1 |
| Zupan, G | 1 |
| Vitezić, M | 1 |
| Ljubicić, D | 1 |
| Simonić, A | 1 |
| Fakhoury, TA | 1 |
| Miller, JM | 1 |
| Sethi, NK | 1 |
| Serati Shirazi, Z | 1 |
| Inaloo, S | 1 |
| Ertam, I | 1 |
| Sezgin, AO | 1 |
| Unal, I | 1 |
| Sellner, J | 1 |
| Buonomano, R | 1 |
| Nedeltchev, K | 1 |
| Findling, O | 1 |
| Schroth, G | 1 |
| Surbek, DV | 1 |
| Leib, SL | 1 |
| Vieker, S | 1 |
| Thiel, M | 1 |
| Längler, A | 1 |
| Large, CH | 2 |
| Kalinichev, M | 1 |
| Lucas, A | 1 |
| Carignani, C | 1 |
| Bradford, A | 1 |
| Garbati, N | 1 |
| Sartori, I | 1 |
| Austin, NE | 1 |
| Ruffo, A | 1 |
| Jones, DN | 1 |
| Alvaro, G | 1 |
| Read, KD | 1 |
| Ferguson, LP | 1 |
| Dargan, PI | 1 |
| Hood, JL | 1 |
| Tibby, SM | 1 |
| van Breemen, MS | 1 |
| Rijsman, RM | 1 |
| Taphoorn, MJ | 1 |
| Walchenbach, R | 1 |
| Zwinkels, H | 1 |
| Vecht, CJ | 1 |
| Frey, LC | 1 |
| Strom, LA | 1 |
| Shrestha, A | 1 |
| Spitz, MC | 1 |
| Łukawski, K | 1 |
| Swiderska, G | 1 |
| Arora, T | 1 |
| Mehta, AK | 1 |
| Sharma, KK | 2 |
| Mediratta, PK | 2 |
| Banerjee, BD | 1 |
| Garg, GR | 1 |
| Sharma, AK | 1 |
| Quan, QY | 1 |
| Yang, F | 1 |
| Wang, JC | 1 |
| Zhao, G | 1 |
| Jiang, W | 1 |
| Antkiewicz-Michaluk, L | 1 |
| Glauser, TA | 1 |
| Cnaan, A | 1 |
| Shinnar, S | 1 |
| Hirtz, DG | 1 |
| Dlugos, D | 1 |
| Masur, D | 1 |
| Clark, PO | 1 |
| Capparelli, EV | 1 |
| Adamson, PC | 1 |
| Close, BR | 1 |
| Banks, CJ | 1 |
| Sienaert, P | 1 |
| Roelens, Y | 1 |
| Demunter, H | 1 |
| Vansteelandt, K | 1 |
| Peuskens, J | 1 |
| Van Heeringen, C | 1 |
| Filip, D | 1 |
| Baulac, M | 1 |
| Leon, T | 1 |
| Whalen, E | 1 |
| Barrett, J | 1 |
| Di Memmo, J | 1 |
| Shukla, R | 1 |
| Lee, YY | 1 |
| Poverennova, I | 1 |
| Demchenko, V | 1 |
| Saiers, J | 1 |
| Adams, B | 1 |
| Hammer, A | 1 |
| Messenheimer, J | 2 |
| Barczyński, B | 1 |
| Buszewicz, G | 1 |
| Bańka, K | 1 |
| Tutaj, K | 1 |
| Wielosz, M | 1 |
| Mądro, R | 1 |
| Finsterer, J | 1 |
| Barton, P | 1 |
| Post, RM | 5 |
| Weiss, SR | 4 |
| Bodenstein-Sachar, H | 1 |
| Gandelman-Marton, R | 1 |
| Ben-Zeev, B | 1 |
| Chapman, J | 1 |
| Blatt, I | 1 |
| Agarwal, NB | 1 |
| Agarwal, NK | 1 |
| Velizarova, R | 1 |
| Gelisse, P | 1 |
| Pageaux, GP | 1 |
| Genton, P | 1 |
| Crespel, A | 1 |
| Yger, M | 1 |
| Khalil, A | 1 |
| Hammoudi, N | 1 |
| Muresan, IP | 1 |
| Alamowitch, S | 1 |
| Tai, P | 1 |
| Dalmau, J | 1 |
| Wennberg, R | 1 |
| Skalli, S | 1 |
| Soulaymani Bencheikh, R | 1 |
| Ikeda, H | 2 |
| Imai, K | 1 |
| Shigematsu, H | 1 |
| Shishido, T | 1 |
| Takayama, R | 1 |
| Fujiwara, T | 1 |
| Takahashi, Y | 1 |
| Inoue, Y | 1 |
| Waldo, SW | 1 |
| Treit, K | 1 |
| Goldschlager, N | 1 |
| Sugiura, C | 1 |
| Matsumura, W | 1 |
| Togawa, M | 1 |
| Maegaki, Y | 1 |
| Ohno, K | 1 |
| Fleurat, M | 1 |
| Smollin, C | 1 |
| Szűcs, A | 1 |
| Rásonyi, G | 1 |
| Orbay, P | 1 |
| Sólyom, A | 1 |
| Holló, A | 1 |
| Arányi, Z | 1 |
| Janszky, J | 1 |
| Erőss, L | 1 |
| Kamondi, A | 1 |
| Kang, HC | 1 |
| Hu, Q | 1 |
| Liu, XY | 1 |
| Xu, F | 1 |
| Li, X | 1 |
| Liu, ZG | 1 |
| Zeng, Z | 1 |
| Wang, M | 1 |
| Zhu, SQ | 1 |
| Huang, HY | 1 |
| Chen, SD | 1 |
| Shaw, FZ | 1 |
| Cuadrado, A | 2 |
| de las Cuevas, I | 1 |
| Valdizán, EM | 1 |
| Armijo, JA | 2 |
| Zucchini, S | 1 |
| Buzzi, A | 1 |
| Bergamaschi, M | 1 |
| Pietra, C | 1 |
| Villetti, G | 1 |
| Simonato, M | 1 |
| Zhang, ZJ | 1 |
| Russell, S | 1 |
| Obeng, K | 1 |
| Postma, T | 2 |
| Obrocea, G | 1 |
| Stratton, SC | 2 |
| Cox, B | 1 |
| Davies, G | 1 |
| Hagan, RM | 1 |
| Bravo, J | 1 |
| Castel-Branco, M | 1 |
| Lebre, V | 1 |
| Falcão, A | 1 |
| Figueiredo, I | 1 |
| Caramona, M | 1 |
| Tandon, M | 1 |
| Anuradha, K | 1 |
| Pandhi, P | 1 |
| Kaminow, L | 1 |
| Schimschock, JR | 1 |
| Bajaj, K | 1 |
| Kumar, A | 1 |
| Jonker, DM | 1 |
| Voskuyl, RA | 1 |
| Danhof, M | 1 |
| Hsu, D | 1 |
| Sandborg, C | 1 |
| Hahn, JS | 1 |
| Cerminara, C | 1 |
| Montanaro, ML | 1 |
| Curatolo, P | 1 |
| Seri, S | 1 |
| Cavitt, J | 1 |
| Privitera, M | 1 |
| Arban, R | 1 |
| Maraia, G | 1 |
| Brackenborough, K | 1 |
| Winyard, L | 1 |
| Wilson, A | 1 |
| Gerrard, P | 1 |
| Large, C | 1 |
| Ratnaraj, N | 1 |
| Patsalos, PN | 1 |
| Wang-Tilz, Y | 1 |
| Tilz, C | 1 |
| Wang, B | 1 |
| Pauli, E | 1 |
| Koebnick, C | 1 |
| Stefan, H | 1 |
| Szot, P | 1 |
| White, SS | 1 |
| Shen, DD | 1 |
| Anderson, GD | 1 |
| Willmore, LJ | 1 |
| Saie, DJ | 1 |
| Sills, ES | 1 |
| Ab Rahman, AF | 1 |
| Ibrahim, MI | 1 |
| Ismail, HI | 1 |
| Seng, TB | 1 |
| Fix, OK | 1 |
| Peters, MG | 1 |
| Davern, TJ | 1 |
| Gamble, C | 1 |
| Chadwick, DW | 1 |
| Sunder, TR | 2 |
| McKee, JR | 1 |
| Vuongc, A | 1 |
| Leppik, I | 1 |
| Thundiyil, JG | 1 |
| Anderson, IB | 1 |
| Stewart, PJ | 1 |
| Olson, KR | 1 |
| Braga, AJ | 1 |
| Chidley, K | 1 |
| Makus, KG | 1 |
| McCormick, J | 1 |
| Yetimalar, Y | 1 |
| Seçkin, M | 1 |
| Seçil, Y | 1 |
| Başoğlu, M | 1 |
| Peltola, J | 1 |
| Peltola, M | 1 |
| Raitanen, J | 1 |
| Keränen, T | 1 |
| Kharazmi, E | 1 |
| Auvinen, A | 1 |
| Sardo, P | 1 |
| D'Agostino, S | 1 |
| Carletti, F | 1 |
| Rizzo, V | 1 |
| La Grutta, V | 1 |
| Ferraro, G | 1 |
| Schwartz, MD | 1 |
| Geller, RJ | 1 |
| Bootsma, HP | 1 |
| Vos, AM | 1 |
| Hulsman, J | 1 |
| Lambrechts, D | 1 |
| Leenen, L | 1 |
| Majoie, M | 1 |
| Savelkoul, M | 1 |
| Schellekens, A | 1 |
| Aldenkamp, AP | 1 |
| Mills, KC | 1 |
| Drazkowski, JF | 1 |
| Kustra, RP | 1 |
| Blum, DE | 1 |
| Danysz, W | 1 |
| Foreman, MM | 1 |
| Hanania, T | 1 |
| Wilcox, KS | 1 |
| Stables, JP | 1 |
| Eller, M | 1 |
| Jankiewicz, K | 1 |
| Chrościńska-Krawczyk, M | 1 |
| Błaszczyk, B | 1 |
| Kim, W | 1 |
| Kim, JS | 1 |
| An, JY | 1 |
| Lee, SJ | 1 |
| Chung, SR | 1 |
| Kim, YI | 1 |
| Lee, KS | 1 |
| Goa, KL | 1 |
| Ross, SR | 1 |
| Chrisp, P | 1 |
| Rataud, J | 1 |
| Debarnot, F | 1 |
| Mary, V | 1 |
| Pratt, J | 1 |
| Stutzmann, JM | 1 |
| Pisani, F | 1 |
| Di Perri, R | 1 |
| Richens, A | 1 |
| Hennessy, MJ | 1 |
| Wiles, CM | 1 |
| De Sarro, G | 1 |
| Nava, F | 1 |
| Aguglia, U | 1 |
| De Sarro, A | 1 |
| Haider, A | 1 |
| Tuchek, JM | 1 |
| Haider, S | 1 |
| Mims, J | 1 |
| Penovich, P | 1 |
| Ritter, F | 1 |
| Frost, MD | 1 |
| Bhaumik, S | 1 |
| Branford, D | 1 |
| Duggirala, C | 1 |
| Ismail, IA | 1 |
| Chaffin, JJ | 1 |
| Davis, SM | 1 |
| Xiong, ZQ | 1 |
| Stringer, JL | 1 |
| Khan, GM | 1 |
| Manil, J | 1 |
| Ebinger, G | 1 |
| Michotte, Y | 1 |
| Barron, TF | 1 |
| Hunt, SL | 1 |
| Peano, C | 1 |
| Leikin, JB | 1 |
| Hanashiro, PK | 1 |
| Lilley, LL | 1 |
| Guanci, R | 1 |
| Motte, J | 1 |
| Trevathan, E | 1 |
| Arvidsson, JF | 1 |
| Barrera, MN | 1 |
| Mullens, EL | 2 |
| Manasco, P | 1 |
| Karpova, MN | 1 |
| Abrosimov, IIu | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Raevskiĭ, KS | 1 |
| Vriend, J | 1 |
| Alexiuk, NA | 1 |
| Dulac, O | 1 |
| Kaminska, A | 1 |
| Giorgi, L | 3 |
| Young, F | 1 |
| Buoni, S | 1 |
| Grosso, S | 1 |
| Fois, A | 1 |
| Otsuki, K | 1 |
| Morimoto, K | 1 |
| Yamada, N | 1 |
| Kuroda, S | 1 |
| Attwell, PJ | 1 |
| Singh Kent, N | 1 |
| Jane, DE | 1 |
| Croucher, MJ | 1 |
| Bradford, HF | 1 |
| Barr, PA | 1 |
| Buettiker, VE | 1 |
| Antony, JH | 1 |
| Verma, A | 1 |
| Miller, P | 1 |
| Carwile, ST | 1 |
| Husain, AM | 1 |
| Radtke, RA | 1 |
| Krupp, E | 2 |
| Heynen, T | 1 |
| Li, XL | 2 |
| Léthel, V | 1 |
| Chabrol, B | 1 |
| Livet, MO | 1 |
| Mancini, J | 1 |
| Risner, ME | 1 |
| Mewasingh, L | 1 |
| Aylett, S | 1 |
| Kirkham, F | 1 |
| Stanhope, R | 1 |
| Bhushan, M | 1 |
| Brooke, R | 1 |
| Hewitt-Symonds, M | 1 |
| Craven, NM | 1 |
| August, PJ | 1 |
| Showalter, PE | 1 |
| Kimmel, DN | 1 |
| Gomez, G | 1 |
| O'Neill, F | 1 |
| Risner, M | 1 |
| D'Arcangelo, G | 1 |
| Tancredi, V | 1 |
| Avoli, M | 1 |
| Braga, MF | 1 |
| Aroniadou-Anderjaska, V | 1 |
| Li, H | 1 |
| Stanková, L | 1 |
| Kubová, H | 1 |
| Mares, P | 1 |
| Leach, MJ | 1 |
| Baxter, MG | 1 |
| Critchley, MA | 1 |
| O'Donnell, RA | 1 |
| Miller, AA | 1 |
| Mikati, MA | 1 |
| Schachter, SC | 1 |
| Schomer, DL | 1 |
| Keally, M | 1 |
| Osborne-Shafer, P | 1 |
| Seaman, CA | 1 |
| Sheridan, PH | 1 |
| Ashworth, M | 1 |
| Kupferberg, H | 1 |
| Valakas, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An International, Double-blind, Parallel-group, Placebo-controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures[NCT00464269] | Phase 3 | 400 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥16 to 80 Years Old) With Partial Onset Seizures[NCT01261325] | Phase 3 | 768 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.[NCT00490035] | Phase 3 | 399 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy: A Randomized, add-on Placebo-controlled Clinical Trial[NCT03590197] | Phase 4 | 104 participants (Actual) | Interventional | 2018-08-06 | Completed | ||
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study[NCT00088452] | Phase 3 | 453 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| A Multicenter, Double-blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-Release Adjunctive Therapy in Patients With Primary Generalized Tonic-Clonic Seizures[NCT00104416] | Phase 3 | 153 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures[NCT00355082] | Phase 3 | 226 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma[NCT00739154] | 200 participants (Anticipated) | Observational | 2008-11-30 | Not yet recruiting | |||
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"There are three different types of seizures:~Type I: Partial seizures~Type II: Generalized seizures~Type III: Unclassified epileptic seizures.~All seizure frequency per week over Treatment Period (TP) was calculated as: (Total number of seizures over the TP)*7/(Total number of days with no missing seizure count in the TP)" (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | seizures per week (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.15 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.80 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 1.96 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 1.77 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.79 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4.26 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 6.36 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 3.37 |
"The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item.~The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 1.97 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 7.03 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 7.73 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 2.06 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.14 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.69 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 2.07 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 1.97 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 6.41 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 2.24 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 3.94 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 0.45 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 8.1 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 6.9 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 7.3 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 5.5 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 7.44 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 7.32 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 6.55 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 7.99 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression. The HADS was developed as a self administered scale to assess the presence and severity of both anxiety and depression simultaneously. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. A negative value in change from Baseline shows an improvement in HADS from Baseline. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 5.36 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4.97 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 4.82 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 5.81 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 1.02 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | -2.61 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 0.73 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 6.07 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00464269)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 5.49 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 3.39 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 3.66 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 2.33 |
"The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item.~The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 9.36 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 3.34 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 3.69 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 5.97 |
"The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-items subscales - seizure worry (5 items), overall quality of life (2 items), emotional well-being (5 items), energy / fatigue (4 items), cognitive functioning (6 items), medication effects (3 items), and social function (5 items) - and a health status item.~The subscale scores, the total score and the health status item score range from 0 to 100 and higher scores indicating better function." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 3.88 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4.07 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 5.19 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 2.88 |
"Partial (Type I) seizures can be classified into one of the following three groups:~Simple partial seizures~Complex partial seizures~Partial seizures evolving to generalized tonic-clonic convulsions.~Partial Onset Seizure (POS) Frequency per week over the Treatment Period (TP) was calculated as:~(Total Type I seizures over the TP)*7/(Total number of days with no missing seizure count in the TP)" (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | seizures per week (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 2.15 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.80 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 1.96 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 1.70 |
"Percent change from Baseline was calculated as percent reduction by:~(weekly seizure frequency Baseline - weekly seizure frequency Treatment)*100/(weekly seizure frequency Baseline).~The higher the values for percent change in Partial Onset Seizure (POS) frequency, the higher the improvement from Baseline." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | Percent change in POS frequency (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 17.75 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 19.95 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 22.52 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 30.47 |
The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 56.3 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 50.0 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 77.8 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 63.6 |
The time to fifth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of fifth Type I seizure. Subjects withdrawing during the Treatment Period before having a fifth Type I seizure were considered as having a fifth Type I seizure on the last day of their Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | days (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 15 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 14 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 17 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 19 |
The time to first Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of first Type I seizure. Subjects withdrawing during the Treatment Period before having a first Type I seizure were considered as having a first Type I seizure on the last day of their Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | days (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 3 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 4 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 5 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 4 |
The time to tenth Partial Onset Seizure (POS) in the Treatment Period is defined as the time between beginning of the Treatment Period and the date of occurrence of tenth Type I seizure. Subjects withdrawing during the Treatment Period before having a tenth Type I seizure were considered as having a tenth Type I seizure on the last day of their Treatment Period. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | days (Median) |
|---|---|
| Modified Intention-to-Treat (Placebo Treated Subjects) | 28 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 30 |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 34 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 37 |
"Subjects were classified in 1 of the following categories based on their percent reduction from Baseline to Treatment Period in Partial Onset Seizure (POS) frequency per week: <-25 %, -25 % to <25 %, 25 % to <50 %, 50 % to <75 %, 75 % to <100 %, and 100 %.~Subjects having zero for Baseline seizure frequency per week were classified in the <-25 % category." (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| <-25 % | -25 % to < 25 % | 25 % to < 50 % | 50 % to < 75 % | 75 % to < 100 % | 100 % | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 14.1 | 38.4 | 24.2 | 15.2 | 6.1 | 2.0 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 21.9 | 31.3 | 25.0 | 12.5 | 8.3 | 1.0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 9.9 | 31.7 | 25.7 | 19.8 | 8.9 | 4.0 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 14.6 | 44.8 | 24.0 | 12.5 | 4.2 | 0 |
The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The investigator completed it by answering to the following: 'Assess the overall change in the severity of patient's illness, compared to start of study medication.' (NCT00464269)
Timeframe: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 17.2 | 18.2 | 31.3 | 32.3 | 1.0 | 0 | 0 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 12.2 | 18.9 | 24.4 | 34.4 | 2.2 | 7.8 | 0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 16.3 | 27.6 | 24.5 | 25.5 | 2.0 | 3.1 | 1.0 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 12.6 | 20.0 | 21.1 | 41.1 | 3.2 | 1.1 | 1.1 |
Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject completed it by answering to the following: 'Overall, has there been a change in your seizures since the start of the study medication?' (NCT00464269)
Timeframe: Baseline to Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | percentage of participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 18.8 | 26.3 | 21.3 | 27.5 | 1.3 | 3.8 | 1.3 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 19.8 | 24.7 | 18.5 | 23.5 | 6.2 | 7.4 | 0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 26.7 | 19.8 | 22.1 | 23.3 | 4.7 | 1.2 | 2.3 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 15.5 | 25.0 | 23.8 | 28.6 | 4.8 | 1.2 | 1.2 |
The responder rate was presented as the number of responders and non-responders. A subject is a responder, if the subject has at least 50 % reduction in partial onset seizure frequency per week from Baseline to Treatment Period. Subjects with zero seizure frequency per week at Baseline were considered as non-responders. (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 23 | 76 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 21 | 75 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 33 | 68 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 16 | 80 |
"Subjects were considered seizure free if their seizure counts for every day over the Treatment Period (TP) was zero and if they did not discontinue before the end of the TP. Seizure freedom rate was calculated as:~(total number of seizure - free subjects in treatment group during TP)/(total number of evaluable Intent-To-Treat (ITT) subjects in treatment group)" (NCT00464269)
Timeframe: Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Seizure-free | No seizures but non-completer | Not seizure-free | |
| Modified Intention-to-Treat (BRV 20 mg/Day Treated Subjects) | 1.0 | 1.0 | 98.0 |
| Modified Intention-to-Treat (BRV 5 mg/Day Treated Subjects) | 1.0 | 0 | 99.0 |
| Modified Intention-to-Treat (BRV 50 mg/Day Treated Subjects) | 4.0 | 0 | 96.0 |
| Modified Intention-to-Treat (Placebo Treated Subjects) | 0 | 0 | 100.0 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | number of seizures/ 28-day (Median) |
|---|---|
| Placebo | 8.7 |
| Brivaracetam 100 mg/Day | 6.3 |
| Brivaracetam 200 mg/Day | 5.8 |
(NCT01261325)
Timeframe: Baseline to 12 week Treatment Period
| Intervention | percentage of change (Median) |
|---|---|
| Placebo | 17.6 |
| Brivaracetam 100 mg/Day | 37.2 |
| Brivaracetam 200 mg/Day | 35.6 |
Primary endpoint: United States of America (FDA) (NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | Percentage of reduction (Number) |
|---|---|
| Brivaracetam 100 mg/Day | 22.8 |
| Brivaracetam 200 mg/Day | 23.2 |
| Placebo | 0 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | days (Median) |
|---|---|
| Placebo | 16 |
| Brivaracetam 100 mg/Day | 21 |
| Brivaracetam 200 mg/Day | 23 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | days (Median) |
|---|---|
| Placebo | 3 |
| Brivaracetam 100 mg/Day | 5 |
| Brivaracetam 200 mg/Day | 6 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | days (Median) |
|---|---|
| Placebo | 32 |
| Brivaracetam 100 mg/Day | 37 |
| Brivaracetam 200 mg/Day | 43 |
Primary Endpoint: European Regulatory Authorities A responder is a participant who experienced a 50% or greater reduction in partial onset seizure (Type I) frequency over the Treatment Period standardized to a 28-day duration. (NCT01261325)
Timeframe: Baseline to 12 week Treatment Period
| Intervention | Percentage of subjects (Number) | |
|---|---|---|
| Responders | Non-Responders | |
| Brivaracetam 100 mg/Day | 38.9 | 61.1 |
| Brivaracetam 200 mg/Day | 37.8 | 62.2 |
| Placebo | 21.6 | 78.4 |
(NCT01261325)
Timeframe: Baseline to 12 week Treatment Period
| Intervention | percentage of subjects (Number) | |||||
|---|---|---|---|---|---|---|
| <-25 % | -25 % to <25 % | 25 % to <50 % | 50 % to <75 % | 75 % to <100 % | 100 % | |
| Brivaracetam 100 mg/Day | 14.3 | 28.6 | 18.3 | 19.0 | 13.9 | 6.0 |
| Brivaracetam 200 mg/Day | 10.8 | 29.3 | 22.1 | 18.1 | 13.7 | 6.0 |
| Placebo | 16.6 | 40.5 | 21.2 | 13.9 | 6.9 | 0.8 |
(NCT01261325)
Timeframe: 12 week Treatment Period
| Intervention | percentage of subjects (Number) | ||
|---|---|---|---|
| Seizure free | No seizures but discontinued | Not seizure free | |
| Brivaracetam 100 mg/Day | 5.2 | 1.2 | 93.7 |
| Brivaracetam 200 mg/Day | 4.0 | 1.2 | 94.8 |
| Placebo | 0.8 | 0.4 | 98.8 |
There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III). (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Times per week (Median) |
|---|---|
| Placebo | 1.75 |
| Brivaracetam 20 mg/Day | 1.34 |
| Brivaracetam 50 mg/Day | 1.49 |
| Brivaracetam 100 mg/Day | 1.26 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 1.80 |
| Brivaracetam 20 mg/Day | 5.36 |
| Brivaracetam 50 mg/Day | 1.02 |
| Brivaracetam 100 mg/Day | 0.69 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -2.09 |
| Brivaracetam 20 mg/Day | 3.35 |
| Brivaracetam 50 mg/Day | 3.09 |
| Brivaracetam 100 mg/Day | 3.50 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 3.80 |
| Brivaracetam 20 mg/Day | 3.75 |
| Brivaracetam 50 mg/Day | 3.13 |
| Brivaracetam 100 mg/Day | -2.45 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 3.49 |
| Brivaracetam 20 mg/Day | 3.53 |
| Brivaracetam 50 mg/Day | 1.95 |
| Brivaracetam 100 mg/Day | 1.99 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 6.6 |
| Brivaracetam 20 mg/Day | 6.9 |
| Brivaracetam 50 mg/Day | 9.7 |
| Brivaracetam 100 mg/Day | 4.9 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -1.54 |
| Brivaracetam 20 mg/Day | -0.59 |
| Brivaracetam 50 mg/Day | -0.41 |
| Brivaracetam 100 mg/Day | 0.08 |
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.65 |
| Brivaracetam 20 mg/Day | -0.10 |
| Brivaracetam 50 mg/Day | 0.26 |
| Brivaracetam 100 mg/Day | -0.24 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.92 |
| Brivaracetam 20 mg/Day | 3.64 |
| Brivaracetam 50 mg/Day | -0.85 |
| Brivaracetam 100 mg/Day | 3.00 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 5.11 |
| Brivaracetam 20 mg/Day | 4.52 |
| Brivaracetam 50 mg/Day | 4.55 |
| Brivaracetam 100 mg/Day | 2.24 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 8.25 |
| Brivaracetam 20 mg/Day | 6.23 |
| Brivaracetam 50 mg/Day | 5.34 |
| Brivaracetam 100 mg/Day | 8.04 |
The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 2.29 |
| Brivaracetam 20 mg/Day | 4.50 |
| Brivaracetam 50 mg/Day | 3.09 |
| Brivaracetam 100 mg/Day | 1.78 |
"The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: Assess the Overall change in the severity of patient's illness, compared to start of study medication." (NCT00490035)
Timeframe: Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 4.78 |
| Brivaracetam 20 mg/Day | 4.99 |
| Brivaracetam 50 mg/Day | 4.99 |
| Brivaracetam 100 mg/Day | 5.34 |
Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Seizure Frequency per Week (Median) |
|---|---|
| Placebo | 1.75 |
| Brivaracetam 20 mg/Day | 1.34 |
| Brivaracetam 50 mg/Day | 1.49 |
| Brivaracetam 100 mg/Day | 1.26 |
"The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: Overall, has there been a change in your seizures since the start of the study medication?" (NCT00490035)
Timeframe: Last Visit or Early Discontinuation Visit in the 12-week Treatment Period
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 4.93 |
| Brivaracetam 20 mg/Day | 5.17 |
| Brivaracetam 50 mg/Day | 5.04 |
| Brivaracetam 100 mg/Day | 5.47 |
The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) * 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percent change in seizures per week (Median) |
|---|---|
| Placebo | -17.03 |
| Brivaracetam 20 mg/Day | -30.03 |
| Brivaracetam 50 mg/Day | -26.83 |
| Brivaracetam 100 mg/Day | -32.45 |
The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 45.9 |
| Brivaracetam 20 mg/Day | 47.2 |
| Brivaracetam 50 mg/Day | 62.5 |
| Brivaracetam 100 mg/Day | 41.0 |
The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Days (Median) |
|---|---|
| Placebo | 19 |
| Brivaracetam 20 mg/Day | 25 |
| Brivaracetam 50 mg/Day | 24 |
| Brivaracetam 100 mg/Day | 24 |
The time to first Type I Seizure during the 12-week Treatment Period was measured in days. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Days (Median) |
|---|---|
| Placebo | 4 |
| Brivaracetam 20 mg/Day | 6 |
| Brivaracetam 50 mg/Day | 6 |
| Brivaracetam 100 mg/Day | 4 |
The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Days (Median) |
|---|---|
| Placebo | 39 |
| Brivaracetam 20 mg/Day | 49 |
| Brivaracetam 50 mg/Day | 40 |
| Brivaracetam 100 mg/Day | 46 |
"The categories are:~<= 25 %~- 25 % to < 25 %~25 % to < 50 %~50 % to < 75 %~75 % to < 100 %~100 %" (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percentage of Participants (Number) | |||||
|---|---|---|---|---|---|---|
| <= 25 % | - 25 % to < 25 % | 25 % to < 50 % | 50 % to < 75 % | 75 % to < 100 % | 100 % | |
| Brivaracetam 100 mg/Day | 10.0 | 33.0 | 21.0 | 14.0 | 18.0 | 4.0 |
| Brivaracetam 20 mg/Day | 10.1 | 35.4 | 27.3 | 18.2 | 7.1 | 2.0 |
| Brivaracetam 50 mg/Day | 15.2 | 33.3 | 24.2 | 17.2 | 9.1 | 1.0 |
| Placebo | 19.0 | 41.0 | 20.0 | 12.0 | 8.0 | 0 |
"Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week.~The Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a >= 50 % reduction in seizure frequency per week from Baseline." (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Non-responders | Responders | |
| Brivaracetam 100 mg/Day | 64.0 | 36.0 |
| Brivaracetam 20 mg/Day | 72.7 | 27.3 |
| Brivaracetam 50 mg/Day | 72.7 | 27.3 |
| Placebo | 80.0 | 20.0 |
Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period. (NCT00490035)
Timeframe: From Baseline to 12-week Treatment Period
| Intervention | Percentage of Participants (Number) | ||
|---|---|---|---|
| Seizure free | No Seizures but non-completer | Not Seizure-free | |
| Brivaracetam 100 mg/Day | 4.0 | 0 | 96.0 |
| Brivaracetam 20 mg/Day | 2.0 | 0 | 98.0 |
| Brivaracetam 50 mg/Day | 0 | 1.0 | 99.0 |
| Placebo | 0 | 0 | 100.0 |
A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 35 |
| Lamotrigine | 25 |
| Valproic Acid | 52 |
Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 12 months of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 70 |
| Lamotrigine | 31 |
| Valproic Acid | 64 |
Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 81 |
| Lamotrigine | 43 |
| Valproic Acid | 85 |
Change from baseline in body weight is calculated as the Week 19 (or last on-study measurement in Double-Blind Treatment Phase) value minus the Baseline value. (NCT00104416)
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
| Intervention | kilograms (Median) |
|---|---|
| Double-Blind Phase: Placebo | 1.00 |
| Double-Blind Phase: LTG XR | 0.00 |
The AEP is a list of 19 items covering many possible side effects attributable to drug treatment. The participants respond by assessing how much each event has been a problem for them over the past 4 weeks (1=Never a Problem to 4=Always a Problem). Each individual item can be examined; an overall adverse events score is calculated as the sum of the scores across the 19 items. The AEP total score ranges from 19 to 76, with a higher score indicating a higher degree of adverse event severity. (NCT00104416)
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| Double-Blind Phase: Placebo | 3.0 |
| Double-Blind Phase: LTG XR | 1.4 |
The 20-item CES-D questionnaire is self-administered and asks respondents to report the frequency to which the 20 events were experienced over the past week. A 4-point Likert scale is used and ranges from rarely or none of the time (0) to most or all of the time (3). The total score, a sum across the 20 items (ranging from 0 to 60), determines the extent to which a participant may be experiencing depression. Higher scores indicate a higher severity of depression. (NCT00104416)
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| Double-Blind Phase: Placebo | 2.9 |
| Double-Blind Phase: LTG XR | 2.4 |
The ESS is an 8-item, self-administered questionnaire that measures excessive daytime sleepiness in adults. The instrument captures information on the extent to which the participant would be likely, or not, to fall asleep in certain situations. The stimulus question is: How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just tired? Questions are answered on a 4-point scale (would never doze [0] to high chance of dozing [3]). The total score ranges from 0 to 24, where a higher score indicates a higher chance of dozing. (NCT00104416)
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| Double-Blind Phase: Placebo | -0.6 |
| Double-Blind Phase: LTG XR | 1.0 |
The NDDI-E is a self-reported questionnaire composed of 46 brief phrases/words to identify mood disorders across the spectrum of depression. It was developed to capture depressive moods that are co-morbid with the disease of epilepsy or its treatment as well as to measure the depressive state of the participant. All phrases are measured on a 4-point Likert scale of Never (1) to Always/often (4) and refer to the participants' mood over the past week. Scoring is comprised of a total mood score calculated by summing the scores of 6 specific items (from 6=never to 24=always or often). (NCT00104416)
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| Double-Blind Phase: Placebo | -0.1 |
| Double-Blind Phase: LTG XR | -2.4 |
The POMS is a self-administered 65-item questionnaire that evaluates the participants' perception of their mood state in 6 areas: tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment. Items are rated on a 5-point Likert scale from 0 (not at all) to 4 (extremely), with higher scores indicating a more negative mood state. A total score (from 0 to 24) is obtained by summing the scores of the six domains. (NCT00104416)
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| Double-Blind Phase: Placebo | 2.4 |
| Double-Blind Phase: LTG XR | 9.7 |
The QOLIE-31 is a 31-item questionnaire that evaluates the participants' perception of his or her quality of life in 7 domains: seizure worry, emotional well being, energy/fatigue, cognitive functioning, medication effects, social functioning, and overall quality of life. Each domain (with scores ranging from 0 to 100) is summed and divided by the total number of questions that were answered. The overall score is derived by weighting and then summing up the seven domain scores. (NCT00104416)
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| Double-Blind Phase: Placebo | -6.5 |
| Double-Blind Phase: LTG XR | -8.5 |
The SSQ is a self-reported instrument developed to assess the severity of seizures and seizure symptoms. The scale consists of 10 major clinical features/symptoms of seizures that the participants rate on a 7-point Likert scale (ranging from very mild/helpful/no bother at all [1] to very severe/no help/bothersome [7]). The Global Bother Domain is the primary score used for the analysis of the SSQ and has scores ranging from 1 to 7. (NCT00104416)
Timeframe: Baseline and Week 19 (or last on-study measurement in Double-Blind Treatment Phase)
| Intervention | points on a scale (Least Squares Mean) |
|---|---|
| Double-Blind Phase: Placebo | 0.86 |
| Double-Blind Phase: LTG XR | 1.23 |
Percent change from baseline is calculated as the number of seizures by week during the Double-Blind Treatment Phase (Treatment Week 1 up to Week 19) compared to the number of seizures per week during the Baseline Phase (Baseline Week 1 up to Week 8). A positive number equals a reduction in seizure frequency. PGTC seizures are more commonly known as gran mal seizures. (NCT00104416)
Timeframe: Baseline through end of Double-Blind Treatment Phase (up to Week 19)
| Intervention | percent change (Median) |
|---|---|
| Double-Blind Phase: Placebo | 32.1 |
| Double-Blind Phase: LTG XR | 75.4 |
Change in seizure frequency was calculated as the average seizure frequency during each of the following: the Entire DB Treatment Phase (Treatment Week 1 up to Week 19); the Escalation Phase (Treatment Week 1 up to Week 7); the Maintenance Phase (Treatment Week 8 up to Week 19); and the last 8 weeks of the Maintenance Phase (Treatment Week 12 up to Week 19), minus the seizure frequency at Baseline. (NCT00104416)
Timeframe: Entire DB Treatment Phase (Treatment Week 1 up to Week 19), Escalation Phase (Treatment Week 1 up to Week 7), Maintenance Phase (Treatment Week 8 up to Week 19), and the last 8 weeks of the Maintenance Phase (Treatment Week 12 up to Week 19)
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >=25% reduction, Entire DB TP, n=72, 69 | >=50% reduction, Entire DB TP, n=72, 69 | >=75% reduction, Entire DB TP, n=72, 69 | 100% reduction, Entire DB TP, n=72, 69 | >=25% reduction, Escalation Phase, n=72, 69 | >=50% reduction, Escalation Phase, n=72, 69 | >=75% reduction, Escalation Phase, n=72, 69 | 100% reduction, Escalation Phase, n=72, 69 | >=25% reduction, Maintenance Phase, n=70, 68 | >=50% reduction, Maintenance Phase, n=70, 68 | >=75% reduction, Maintenance Phase, n=70, 68 | 100% reduction, Maintenance Phase, n=70, 68 | >=25% reduction, Last 8 Weeks of MP, n=70, 68 | >=50% reduction, Last 8 Weeks of MP, n=70, 68 | >=75% reduction, Last 8 Weeks of MP, n=70, 68 | 100% reduction, Last 8 Weeks of MP, n=70, 68 | |
| Double-Blind Phase: LTG XR | 56 | 48 | 35 | 14 | 51 | 38 | 24 | 15 | 60 | 51 | 40 | 31 | 61 | 54 | 44 | 35 |
| Double-Blind Phase: Placebo | 43 | 23 | 14 | 7 | 39 | 23 | 14 | 9 | 46 | 29 | 14 | 10 | 47 | 29 | 18 | 15 |
Change in seizure frequency was calculated as the average seizure frequency during each of the following: the Entire CP (CP Week 1 up to Week 52); the Transition Phase (CP Week 1 up to Week 7); the Open-Label (OL) Phase (CP Week 8 up to Week 52); and the last 8 weeks of the Open Label Phase (CP Week 45 up to Week 52) minus the seizure frequency at Baseline. W, Week. (NCT00104416)
Timeframe: Entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52)
| Intervention | participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >=25% reduction, Entire CP, n=68, 66, 24 | >=50% reduction, Entire CP, n=68, 66, 24 | >=75% reduction, Entire CP, n=68, 66, 24 | 100% reduction, Entire CP, n=68, 66, 24 | >=50% increase, Entire CP, n=68, 66, 24 | >=25% reduction, Transition Phase, n=68, 66, 20 | >=50% reduction, Transition Phase, n=68, 66, 20 | >=75% reduction, Transition Phase, n=68, 66, 20 | 100% reduction, Transition Phase, n=68, 66, 20 | >=50% increase, Transition Phase, n=68, 66, 20 | >=25% reduction, Open-Label Phase, n=68, 64, 23 | >=50% reduction, Open-Label Phase, n=68, 64, 23 | >=75% reduction, Open-Label Phase, n=68, 64, 23 | 100% reduction, Open-Label Phase, n=68, 64, 23 | >=50% increase, Open-Label Phase, n=68, 64, 23 | >=25% reduction, Last 8 W of OL Phase,n=68, 63, 19 | >=50% reduction, Last 8 W of OL Phase,n=68, 63, 19 | >=75% reduction, Last 8 W of OL Phase,n=68, 63, 19 | 100% reduction, Last 8 W of OL Phase, n=68, 63, 19 | >=50% increase, Last 8 W of OL Phase, n=68, 63, 19 | |
| Baseline Failures | 11 | 11 | 8 | 6 | 10 | 13 | 12 | 12 | 12 | 3 | 12 | 10 | 8 | 6 | 10 | 10 | 10 | 10 | 10 | 4 |
| Continuation Phase: LTG/LTG | 63 | 59 | 49 | 28 | 1 | 60 | 56 | 46 | 41 | 1 | 61 | 57 | 49 | 28 | 1 | 60 | 53 | 47 | 41 | 1 |
| Continuation Phase: Placebo/LTG | 59 | 57 | 46 | 16 | 2 | 51 | 44 | 33 | 27 | 3 | 61 | 56 | 47 | 21 | 2 | 60 | 53 | 45 | 35 | 2 |
The investigators rated the participants' overall clinical status based on 7 clinical factors and an overall factor: seizure frequency, duration, and intensity; adverse experiences; social, intellectual, and motor functioning. Using a 7-point scale (marked deterioration [1], moderate deterioration [2], mild deterioration [3], no change [4], mild improvement [5], moderate improvement [6], or marked improvement [7]), the investigators assessed the participants' status compared to their condition prior to initiating study medication. (NCT00104416)
Timeframe: Week 19 (or last on-study assessment in Double-Blind Treatment Phase)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any improvement, score of 5-7 | No change, score of 4 | Any deterioration, score of 1-3 | |
| Double-Blind Phase: LTG XR | 57 | 10 | 1 |
| Double-Blind Phase: Placebo | 36 | 33 | 2 |
Participants were asked to rate their satisfaction with their seizure control compared to their seizure control prior to initiating study drug on a 7 point scale: marked deterioration (1), moderate deterioration (2), mild deterioration (3), no change (4), mild improvement (5), moderate improvement (6), or marked improvement (7). (NCT00104416)
Timeframe: Week 19 (or last on-study assessment in Double-Blind Treatment Phase)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any improvement, score of 5-7 | No change, score of 4 | Any deterioration, score of 1-3 | |
| Double-Blind Phase: LTG XR | 60 | 6 | 2 |
| Double-Blind Phase: Placebo | 53 | 13 | 5 |
50% reduction in seizure frequency is defined as the time at which a participant first achieved and maintained a >=50% reduction in seizure frequency following exposure to at least 1 week of study drug. (NCT00104416)
Timeframe: Baseline through end of Double-Blind Treatment Phase (up to Week 19)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| 2 weeks | 4 weeks | 8 weeks | 12 weeks | 16 weeks | |
| Double-Blind Phase: LTG XR | 22 | 28 | 39 | 43 | 48 |
| Double-Blind Phase: Placebo | 12 | 12 | 14 | 20 | 23 |
Percent change from baseline is calculated as the number of seizures by week during the Escalation Phase (Treatment Week 1 up to Week 7), the Maintenance Phase (Treatment Week 8 up to Week 19), and during the last 8 weeks of the Maintenance Phase (Treatment Week 12 up to Week 19) compared to the number of seizures per week during the Baseline Phase (Baseline Week 1 up to Week 8). A positive number equals a reduction in seizure frequency. (NCT00104416)
Timeframe: Escalation Phase (Treatment Week 1 up to Week 7), Maintenance Phase (Treatment Week 8 up to Week 19), and the last 8 weeks of the Maintenance Phase (Week 12 up to Week 19)
| Intervention | percent change (Median) | ||
|---|---|---|---|
| Escalation Phase, n=72, 69 | Maintenance Phase, n=70, 68 | Last 8 weeks of the Maintenance Phase, n=70, 68 | |
| Double-Blind Phase: LTG XR | 61.9 | 89.7 | 100.0 |
| Double-Blind Phase: Placebo | 30.6 | 33.3 | 35.4 |
Percent change from baseline is calculated as the number of seizures by week during the entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52) minus the number of seizures per week during the Baseline Phase (Baseline Week 1 through Week 8). A positive number equals a reduction in seizure frequency. (NCT00104416)
Timeframe: Entire CP (CP Week 1 up to Week 52), the Transition Phase (CP Week 1 up to Week 7), the Open-Label Phase (CP Week 8 up to Week 52), and the last 8 weeks of the Open-Label Phase (CP Week 45 up to Week 52)
| Intervention | percent change (Median) | |||
|---|---|---|---|---|
| Entire Continuation Phase, n=68, 66, 24 | Transition Phase, n=68, 66, 20 | Open-Label Phase, n=68, 64, 23 | Last 8 weeks of Open-Label Phase, n=68, 63, 19 | |
| Baseline Failures | 21.7 | 100.0 | 31.7 | 100.0 |
| Continuation Phase: LTG/LTG | 95.1 | 100.0 | 95.0 | 100.0 |
| Continuation Phase: Placebo/LTG | 85.2 | 73.1 | 89.2 | 100.0 |
The number of participants who had no seizures during the treatment period was calculated. The last 12 weeks of treatment were either Weeks 11-22 or 12-23 depending on which background AED was being withdrawn (NCT00355082)
Timeframe: The last 12 weeks of treatment of the Treatment phase (Monotherapy phase - approximately Week 11 through Week 23)
| Intervention | participants (Number) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 22 |
| LTG XR, 250 mg | 8 |
Change from baseline was calculated as the average seizure frequency at the end of the Continuation Phase minus the average seizure frequency at Baseline. The number of seizures during the Continuation phase divided by the number of weeks was compared to the number of seizures at Baseline. A positive number indicates a reduction in seizure frequency. (NCT00355082)
Timeframe: Baseline and start of Continuation phase through Week 24 or end of participation in the Continuation phase
| Intervention | percent change in seizures (Median) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 72.2 |
| Baseline Failures | 68.8 |
Change from Baseline was measured as the number of seizures at Visits 3 through 9 minus the number of seizures at Baseline. The number of partial seizures during treatment divided by the number of weeks of treatment was compared to the weekly seizure frequency during Baseline. A positive number equals a reduction in seizure frequency. (NCT00355082)
Timeframe: Baseline and Study Visit 3 through Visit 9 of the Treatment phase (Treatment Week 0 through Week 23)
| Intervention | percent change in seizures (Median) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 54.8 |
| LTG XR, 250 mg | 52.2 |
The percentage of participants meeting Escape Criteria was calculated as the number of participants who met an Escape Criterion divided by the number who had reached Visit 5 minus major protocol violators. Escape Criteria are: (1) doubling of average monthly seizure frequency; (2) doubling of the highest consecutive 2-day seizure total; (3) occurrence of a new, more severe seizure type; or (4) worsening of generalized tonic-clonic seizures. (NCT00355082)
Timeframe: Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
| Intervention | percentage of participants (Number) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 4 |
| LTG XR, 250 mg | 6 |
The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who had reached Visit 5 minus major protocol violators. The Control group was composed of data from other similar studies and is not part of this study. (NCT00355082)
Timeframe: From Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
| Intervention | percentage of participants (Number) |
|---|---|
| LTG XR, 250 mg | 16 |
The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who reached Visit 5 minus major protocol violators. The Control group is composed of data from other similar studies and is not part of this study. (NCT00355082)
Timeframe: From Study Visit 5 through Visit 9 of the Treatment Phase (approximately Week 7 through Week 23)
| Intervention | percentage of participants (Number) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 12 |
Time (days) until the participant discontinued the study (NCT00355082)
Timeframe: From Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
| Intervention | Days (Mean) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 147.3 |
| LTG XR, 250 mg | 133.2 |
Change in seizure frequency was calculated as the average seizure frequency during the Continuation Phase minus the seizure frequency at Baseline. (NCT00355082)
Timeframe: Baseline and entire Continuation phase (24 Weeks)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| At least a 25% reduction in seizures | At least a 50% reduction in seizures | At least a 75% reduction in seizures | 100% reduction in seizures | At least a 50% increase in seizures | |
| Baseline Failures | 7 | 6 | 3 | 2 | 3 |
| Lamotrigine Extended-release (LTG XR), 300 mg | 169 | 137 | 85 | 38 | 6 |
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
38 reviews available for lamotrigine and Absence Seizure
| Article | Year |
|---|---|
Therapeutic Basis of Generic Substitution of Antiseizure Medications.
Topics: Anticonvulsants; Drug Substitution; Drugs, Generic; Epilepsy; Humans; Lamotrigine; Pharmaceutical Pr | 2022 |
The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches.
Topics: Anticonvulsants; Carbamazepine; Dementia; Epilepsy; Felbamate; Gabapentin; Humans; Inflammasomes; La | 2022 |
[Medical Treatment of Epilepsy].
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Seizures; Valproic Acid | 2023 |
Gabapentin monotherapy for epilepsy: A review.
Topics: Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Gabapentin; | 2023 |
Network Basis of Seizures Induced by Deep Brain Stimulation: Literature Review and Connectivity Analysis.
Topics: Anorexia Nervosa; Anticonvulsants; Brain; Deep Brain Stimulation; Female; Gyrus Cinguli; Hippocampus | 2019 |
The efficacy and safety of lamotrigine for absence seizures in children and adolescents: A systematic review and meta-analysis.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Absence; Female; Humans; Lamotrigine; Male; Seizures | 2020 |
Lamotrigine add-on therapy for drug-resistant focal epilepsy.
Topics: Adult; Anticonvulsants; Ataxia; Child; Cognition; Cross-Over Studies; Diplopia; Dizziness; Drug Resi | 2020 |
Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.
Topics: Adolescent; Anticonvulsants; Child; Epilepsy, Absence; Ethosuximide; Female; Humans; Lamotrigine; Ma | 2021 |
Which treatment strategy in patients with epilepsy with focal seizures uncontrolled by the first anti-seizure medication?
Topics: Animals; Anticonvulsants; Epilepsy; Humans; Lamotrigine; Levetiracetam; Seizures | 2021 |
Initial Management of Seizure in Adults.
Topics: Adolescent; Adult; Anticonvulsants; Diagnosis, Differential; Electroencephalography; Epilepsy; Ethan | 2021 |
Antiepileptic drug treatment of generalized tonic-clonic seizures: An evaluation of regulatory data and five criteria for drug selection.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Drug and Narcotic Control; Drug-Related Side Effect | 2018 |
A Practical Guide to Treatment of Childhood Absence Epilepsy.
Topics: Anticonvulsants; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Electroen | 2019 |
Pregabalin add-on for drug-resistant focal epilepsy.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsies, Partial; Gabapentin | 2019 |
[Epilepsy in the elderly].
Topics: Age Factors; Aged; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Isoxa | 2013 |
Seizures and intracranial hemorrhage.
Topics: Anticonvulsants; Carbamazepine; Congenital Abnormalities; Eclampsia; Epilepsy; Female; Folic Acid; H | 2013 |
Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials.
Topics: Anticonvulsants; Chemistry, Pharmaceutical; Delayed-Action Preparations; Double-Blind Method; Drug A | 2013 |
[Retigabine - a new antiepileptic drug with a different mechanism of action].
Topics: Adult; Anticonvulsants; Carbamates; Drug Interactions; GABA Modulators; Humans; Lamotrigine; Membran | 2013 |
Pharmacotherapy for tonic-clonic seizures.
Topics: Acetamides; Anticonvulsants; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Fructose; Humans; Lacosa | 2014 |
Clinical Management of Seizures in Patients With Low-Grade Glioma.
Topics: Anticonvulsants; Brain Neoplasms; Glioma; Humans; Lamotrigine; Levetiracetam; Piracetam; Seizures; T | 2015 |
Antiepileptic Drugs.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; O | 2016 |
Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Topics: Acetamides; Acute Kidney Injury; Amines; Anticonvulsants; Carbamates; Critical Illness; Cyclohexanec | 2016 |
Emergent complications of the newer anticonvulsants.
Topics: Acidosis; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Overdose; Fructo | 2010 |
Epileptic disorders in pregnancy: an overview.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Folic Acid; Hemorrhag | 2008 |
Seizures secondary to lamotrigine toxicity in a two-year-old.
Topics: Child, Preschool; Humans; Lamotrigine; Male; Seizures; Triazines | 2010 |
Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders.
Topics: Amygdala; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Drug Resistance; Drug Tolerance | 2011 |
Antiepileptic drugs and neuroprotection: current status and future roles.
Topics: Animals; Anticonvulsants; Brain; Epilepsy; Fructose; Humans; Isoxazoles; Lamotrigine; Levetiracetam; | 2005 |
A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Disease-Free Survival; Double-Blind Method; Epilepsies | 2006 |
Optimizing therapy of seizures in women who use oral contraceptives.
Topics: Anticonvulsants; Contraceptives, Oral; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug | 2006 |
[Caffeine and antiepileptic drugs: experimental and clinical data].
Topics: Animals; Anticonvulsants; Caffeine; Carbamazepine; Dose-Response Relationship, Drug; Drug Interactio | 2007 |
Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.
Topics: Animals; Anticonvulsants; Dosage Forms; Drug Evaluation; Drug Interactions; Drug Tolerance; Epilepsy | 1993 |
Seizure control: how to use the new antiepileptic drugs in older patients.
Topics: Acetates; Age Factors; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions | 1996 |
A review of the newer antiepileptic drugs and the ketogenic diet.
Topics: Acetates; Age Factors; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids | 1997 |
Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes.
Topics: Anticonvulsants; Child; Diagnosis, Differential; Epilepsy; Epilepsy, Generalized; Humans; Lamotrigin | 1997 |
Meeting the challenge of epilepsy in persons with multiple handicaps.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Comorbidity; Developmental Disabilities | 1997 |
Safety review of adult clinical trial experience with lamotrigine.
Topics: Adolescent; Adult; Anticonvulsants; Calcium Channel Blockers; Drug Therapy, Combination; Exanthema; | 1998 |
The tolerability of lamotrigine in children.
Topics: Adolescent; Anticonvulsants; Child; Clinical Trials as Topic; Drug Eruptions; Humans; Lamotrigine; S | 2000 |
Lamotrigine--an add-on antiepileptic.
Topics: Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Humans; Lamotrigine; Seizures; Triaz | 1992 |
Neurochemical and behavioral aspects of lamotrigine.
Topics: Animals; Anticonvulsants; Behavior, Animal; Electroshock; Gerbillinae; Glutamates; In Vitro Techniqu | 1991 |
23 trials available for lamotrigine and Absence Seizure
| Article | Year |
|---|---|
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Tolerability and efficacy of adjunctive brivaracetam in adults with focal seizures by concomitant antiseizure medication use: Pooled results from three phase 3 trials.
Topics: Adult; Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Therapy, Combination; Humans; Lamot | 2022 |
Time to baseline seizure count in patients with focal seizures receiving adjunctive eslicarbazepine acetate in a phase IV clinical trial.
Topics: Adult; Anticonvulsants; Dibenzazepines; Double-Blind Method; Humans; Lamotrigine; Levetiracetam; Sei | 2023 |
Efficacy and safety of eslicarbazepine acetate as a first or later adjunctive therapy in patients with focal seizures.
Topics: Anticonvulsants; Dibenzazepines; Double-Blind Method; Humans; Lamotrigine; Levetiracetam; Quality of | 2021 |
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Topics: Adult; Anticonvulsants; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Thera | 2018 |
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Topics: Adult; Anticonvulsants; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Thera | 2018 |
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Topics: Adult; Anticonvulsants; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Thera | 2018 |
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Topics: Adult; Anticonvulsants; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Thera | 2018 |
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Topics: Adult; Anticonvulsants; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Thera | 2018 |
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Topics: Adult; Anticonvulsants; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Thera | 2018 |
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Topics: Adult; Anticonvulsants; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Thera | 2018 |
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Topics: Adult; Anticonvulsants; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Thera | 2018 |
Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Topics: Adult; Anticonvulsants; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Thera | 2018 |
AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies.
Topics: Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Monitoring; Epilepsy; Female; Humans; Lamo | 2018 |
Long-term efficacy and safety of lamotrigine monotherapy in Japanese and South Korean pediatric patients with newly diagnosed typical absence seizures: An open-label extension study.
Topics: Anticonvulsants; Brain; Child; Child, Preschool; Electroencephalography; Epilepsy, Absence; Female; | 2018 |
Tolerability of adjunctive eslicarbazepine acetate according to concomitant lamotrigine or carbamazepine use: A subgroup analysis of three phase III trials in adults with focal (partial-onset) seizures.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Dibenzazepines; Diplopia; Dose-Response Re | 2018 |
Time to 12-month remission and treatment failure for generalised and unclassified epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Electroencephalography; Epilepsy, Generalized; Female; Fr | 2014 |
Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Delayed-Action Preparations; Drug Therapy, Combination; Ep | 2014 |
Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
Topics: Aged; Anticonvulsants; Carbamates; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Co | 2015 |
The effect of recurrent seizures on cognitive, behavioral, and quality-of-life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Cognition; Epilepsies, Partial; Female; Follow-Up Studies; Hu | 2015 |
Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study.
Topics: Affect; Age of Onset; Aged; Aged, 80 and over; Anticonvulsants; Data Interpretation, Statistical; De | 2008 |
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy.
Topics: Adolescent; Analysis of Variance; Anticonvulsants; Attention Deficit and Disruptive Behavior Disorde | 2010 |
A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dizziness; Double-Blind Method; Epilepsies, Partial; Fem | 2010 |
Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Double-Blind Method; Drug Administration Schedule; Drug Th | 2010 |
Analysis of three lamotrigine extended-release clinical trials: comparison of pragmatic ITT and LOCF methodologies.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Delayed-Action Preparations; Dose-Response Relationship, D | 2012 |
[Efficacy and safety of the combined therapy of valproic acid and lamotrigine for epileptics].
Topics: Child; Child, Preschool; Drug Therapy, Combination; Epilepsies, Partial; Epilepsy; Epilepsy, Absence | 2012 |
Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Evaluation | 2003 |
Changes of seizures activity during rapid withdrawal of lamotrigine.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, C | 2005 |
Relative influences of adjunctive topiramate and adjunctive lamotrigine on scanning and the effective field of view.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Cognition; Data Interpretation, Statist | 2008 |
Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Epilepsy; Female; | 1997 |
Lamotrigine treatment in childhood drug resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Cognition; Electroencephalography; Epil | 1998 |
[Lamotrigine therapy in children. Retrospective study of 32 children].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition; Epilepsy; Female; Humans; Lamotrigi | 2000 |
186 other studies available for lamotrigine and Absence Seizure
| Article | Year |
|---|---|
Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives.
Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Bicuculline; Drug Design; Electroshock; Indicators | 1998 |
Design, synthesis, and pharmacological evaluation of conformationally constrained analogues of N,N'-diaryl- and N-aryl-N-aralkylguanidines as potent inhibitors of neuronal Na+ channels.
Topics: Animals; Anticonvulsants; Biological Transport; Brain; Calcium; Calcium Channel Blockers; Calcium Ch | 1998 |
Synthesis and anticonvulsant activity of trans- and cis-2-(2,6-dimethylphenoxy)-N-(2- or 4-hydroxycyclohexyl)acetamides and their amine analogs.
Topics: Acetamides; Amines; Animals; Anticonvulsants; Mice; Rats; Seizures | 2011 |
Chlorophenoxy aminoalkyl derivatives as histamine H(3)R ligands and antiseizure agents.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Electroshock; Humans; Ligands; Male; Mic | 2016 |
[Women with epilepsy before and during pregnancy: a case series of outpatient counseling in a tertiary epilepsy center].
Topics: Anticonvulsants; Counseling; Epilepsy; Female; Folic Acid; Humans; Lamotrigine; Levetiracetam; Outpa | 2022 |
Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
Topics: Adult; Anticonvulsants; Carbamazepine; Chemical and Drug Induced Liver Injury; Chemical and Drug Ind | 2022 |
Lamotrigine and retigabine increase motor threshold in transcranial magnetic stimulation at the dose required to produce an antiepileptic effect against maximal electroshock-induced seizure in rats.
Topics: Animals; Anticonvulsants; Carbamates; Electroshock; Evoked Potentials, Motor; Lamotrigine; Male; Phe | 2022 |
Rational therapy with lamotrigine or levetiracetam: Which one to select?
Topics: Anticonvulsants; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; Humans; Immunoglobulin E; Lam | 2022 |
Trends in the choice of antiseizure medications in juvenile myoclonic epilepsy: A retrospective multi-center study from Turkey between 2010 and 2020.
Topics: Adolescent; Anticonvulsants; Child; Female; Humans; Lamotrigine; Levetiracetam; Male; Myoclonic Epil | 2022 |
Analyzing excipient-related adverse events in antiseizure drug formulations.
Topics: Anticonvulsants; Drug Compounding; Excipients; Gabapentin; Humans; Lamotrigine; Levetiracetam; Seizu | 2022 |
Extrapolation of Efficacy from Adults to Pediatric Patients of Drugs for Treatment of Partial Onset Seizures: A Regulatory Perspective.
Topics: Adult; Anticonvulsants; Child; Humans; Lamotrigine; Levetiracetam; Pharmaceutical Preparations; Seiz | 2022 |
Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anticonvulsants; | 2022 |
Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Lamotrigine; Risk Factors; Seizures; Tri | 2022 |
Efficacy and safety of antiseizure medication in post-stroke epilepsy.
Topics: Anticonvulsants; Epilepsies, Partial; Epilepsy; Humans; Lacosamide; Lamotrigine; Levetiracetam; Seiz | 2022 |
Pharmacotherapeutic management of seizures in patients with Angleman Syndrome.
Topics: Anticonvulsants; Cannabidiol; Child; Clobazam; Clonazepam; Ethosuximide; Humans; Lamotrigine; Leveti | 2022 |
Seizures, behavioral deficits, and adverse drug responses in two new genetic mouse models of
Topics: Animals; Anticonvulsants; Brain Diseases; Child; Humans; Hyperpolarization-Activated Cyclic Nucleoti | 2022 |
Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Pregnancy; Seizures; V | 2023 |
Efficacy of antiseizure medication in a mouse model of HCN1 developmental and epileptic encephalopathy.
Topics: Animals; Anticonvulsants; Epilepsy; Epilepsy, Generalized; Hyperpolarization-Activated Cyclic Nucleo | 2023 |
miR-9a-5p expression is decreased in the hippocampus of rats resistant to lamotrigine: A behavioural, molecular and bioinformatics assessment.
Topics: Animals; Anticonvulsants; Calcium Channels, L-Type; Computational Biology; Hippocampus; Lamotrigine; | 2023 |
Lamotrigine rescues neuronal alterations and prevents seizure-induced memory decline in an Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anticonvulsants; Disease Models, Animal; Hippocam | 2023 |
Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily G, Member 2; Epilepsy; Lamotri | 2023 |
Changes in seizure frequency and anti-seizure medication therapy during pregnancy and one year postpregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; Seizures | 2023 |
Management of epilepsy with eyelid myoclonia: Results of an international expert consensus panel.
Topics: Anticonvulsants; Consensus; Epilepsy, Reflex; Eyelids; Female; Humans; Lamotrigine; Seizures | 2023 |
Empiric dosing strategies to predict lamotrigine concentrations during pregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; Seizures | 2023 |
Changes over 24 years in a pregnancy register - Teratogenicity and epileptic seizure control.
Topics: Anticonvulsants; Australia; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complication | 2023 |
Antiepileptogenic Effects of Anakinra, Lamotrigine and Their Combination in a Lithium-Pilocarpine Model of Temporal Lobe Epilepsy in Rats.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy, Temporal Lobe; Hippocampus; Interleukin | 2023 |
Comparison of plasma, saliva, and hair lamotrigine concentrations.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Chromatography, Liquid; Drug Monitoring; Epilepsy; Female; | 2019 |
Anti-epileptic drug and folic acid usage during pregnancy, seizure and malformation outcomes: Changes over two decades in the Kerala Registry of Epilepsy and Pregnancy.
Topics: Adult; Anticonvulsants; Carbamazepine; Female; Folic Acid; Humans; India; Lamotrigine; Levetiracetam | 2020 |
Pleural Effusion Associated With Use of Lamotrigine.
Topics: Adolescent; Anticonvulsants; Drug Hypersensitivity Syndrome; Humans; Lamotrigine; Lymphohistiocytosi | 2020 |
Delirium Secondary to Lamotrigine Toxicity.
Topics: Adolescent; Adult; Aged; Delirium; Drug Interactions; Female; Humans; Lamotrigine; Male; Middle Aged | 2020 |
Low-frequency Stimulation at the Subiculum is Anti-convulsant and Anti-drug-resistant in a Mouse Model of Lamotrigine-resistant Temporal Lobe Epilepsy.
Topics: Animals; Electric Stimulation Therapy; Epilepsy, Temporal Lobe; Hippocampus; Lamotrigine; Mice; Seiz | 2020 |
Improvement of epilepsy with lacosamide in a patient with ring chromosome 20 syndrome.
Topics: Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsy; Humans; Lacosamide; Lamotri | 2020 |
Sub-additive (antagonistic) interaction of lacosamide with lamotrigine and valproate in the maximal electroshock-induced seizure model in mice: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Drug | 2020 |
Gaze-evoked nystagmus associated with valproic acid-induced lamotrigine toxicity.
Topics: Adult; Anticonvulsants; Epilepsy, Temporal Lobe; Female; Humans; Lamotrigine; Nystagmus, Pathologic; | 2020 |
Antiseizure drug efficacy and tolerability in established and novel drug discovery seizure models in outbred vs inbred mice.
Topics: Animals; Animals, Outbred Strains; Anticonvulsants; Behavior, Animal; Brain; Carbamazepine; Cornea; | 2020 |
Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; China; Epilepsy; Female; Humans | 2020 |
Lamotrigine-associated hemophagocytic lymphohistiocytosis.
Topics: Adult; Anticonvulsants; Biopsy; Bone Marrow; Dexamethasone; Diagnosis, Differential; Etoposide; Huma | 2021 |
Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy, Generalized; Humans; Lamotrigine; Levetiracetam; Myoclonic Epileps | 2021 |
In-silico computational analysis of [6-(2, 3-Dichlorophenyl)-1, 2, 4-Triazine-3, 5-Diamine] metal complexes on voltage gated sodium channel and dihydrofolate reductase enzyme.
Topics: Anticonvulsants; Coordination Complexes; Epilepsy; Humans; Lamotrigine; Seizures; Tetrahydrofolate D | 2020 |
Knowledge of epilepsy among German pharmacists.
Topics: Anticonvulsants; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; L | 2021 |
The molecular and phenotypic spectrum of CLCN4-related epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child Behavior Disorders; Child, Preschool; Chlorid | 2021 |
Interactions among Lacosamide and Second-Generation Antiepileptic Drugs in the Tonic-Clonic Seizure Model in Mice.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Interactions; Drug Synergism; Drug Therapy, C | 2021 |
The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide.
Topics: Anticonvulsants; Epilepsy; Glioma; Humans; Lacosamide; Lamotrigine; Retrospective Studies; Seizures; | 2021 |
Effects of new antiseizure drugs on seizure activity and anxiety-like behavior in adult zebrafish.
Topics: Age Factors; Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Dose-Response Relationship, Dru | 2021 |
Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.
Topics: Hallucinogens; Humans; Lamotrigine; Lithium; Psilocybin; Seizures | 2021 |
Epilepsy and Pregnancy: An Audit of Specialized Care.
Topics: Anticonvulsants; Canada; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; | 2022 |
Micellar buccal film for safe and effective control of seizures: Preparation, in vitro characterization, ex vivo permeation studies and in vivo assessment.
Topics: Animals; Anticonvulsants; Humans; Lamotrigine; Micelles; Pentylenetetrazole; Rats; Seizures | 2021 |
Lamotrigine Drug Interactions in Combination Therapy and the Influence of Therapeutic Drug Monitoring on Clinical Outcomes of Adult Patients.
Topics: Adult; Anticonvulsants; Carbamazepine; Clonazepam; Drug Interactions; Drug Monitoring; Drug Therapy, | 2017 |
Effect of lamotrigine on seizure development in a rat pentylenetetrazole kindling model.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Female; Kindling, Neurologic; Lamotrigin | 2017 |
A survey of antiepileptic drug responses identifies drugs with potential efficacy for seizure control in Wolf-Hirschhorn syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clobazam; Female; Humans | 2018 |
Observational multicentre study into the use of antiepileptic drugs in Spanish neurology consultations.
Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans; Lamotrigine; Levetirace | 2020 |
Double cortex syndrome in a male patient without lissencephaly.
Topics: Adult; Anticonvulsants; Classical Lissencephalies and Subcortical Band Heterotopias; Electroencephal | 2020 |
Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in a mouse tonic-clonic seizure model.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Epileps | 2018 |
Accidental injuries in patients with generalized tonic-clonic seizures. A multicenter, observational, cross-sectional study (QUIN-GTC study).
Topics: Accidental Injuries; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Cross-Sectional St | 2019 |
The effects of lamotrigine and ethosuximide on seizure frequency, neuronal loss, and astrogliosis in a model of temporal-lobe epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electroencephalography; Epilepsy, Temporal Lobe; E | 2019 |
Dronedarone (a multichannel blocker) enhances the anticonvulsant potency of lamotrigine, but not that of lacosamide, pregabalin and topiramate in the tonic-clonic seizure model in mice.
Topics: Animals; Anti-Arrhythmia Agents; Anticonvulsants; Disease Models, Animal; Dronedarone; Drug Synergis | 2019 |
Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy.
Topics: Adult; Anticonvulsants; Drug Monitoring; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy | 2019 |
Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Cohort Studies; Female; Humans; Lamotrigine; Levetiracetam; Male | 2019 |
A 16q22.2-q23.1 deletion identified in a male infant with West syndrome.
Topics: Anticonvulsants; Chromosomes, Human, Pair 16; Epilepsy; Humans; Infant; Intellectual Disability; Lam | 2019 |
Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.
Topics: Animals; Anticonvulsants; Brain; Cannabidiol; Chromatography, High Pressure Liquid; Disease Models, | 2019 |
A man in his 40s with repeated seizures.
Topics: Adult; Anticonvulsants; Bipolar Disorder; Diagnosis, Differential; Humans; Lamotrigine; Male; Middle | 2013 |
Cytisine inhibits the anticonvulsant activity of phenytoin and lamotrigine in mice.
Topics: Alkaloids; Animals; Anticonvulsants; Azocines; Disease Models, Animal; Dose-Response Relationship, D | 2013 |
Ictal bradycardia and asystole in an adult with a focal left insular lesion.
Topics: Anticonvulsants; Benzodiazepines; Bradycardia; Brain Diseases; Cerebral Cortex; Clobazam; Drug Resis | 2013 |
[Comparison of neuroprotective effects of anticonvulsant drugs in brain injury therapy].
Topics: Amines; Animals; Animals, Outbred Strains; Anticonvulsants; Brain; Brain Injuries; Brain Ischemia; C | 2012 |
Cav 2.3 (R-type) calcium channels are critical for mediating anticonvulsive and neuroprotective properties of lamotrigine in vivo.
Topics: Acetamides; Animals; Anticonvulsants; Calcium Channels, R-Type; Cation Transport Proteins; Disease M | 2013 |
Seizure control and treatment changes in pregnancy: observations from the EURAP epilepsy pregnancy registry.
Topics: Anticonvulsants; Carbamazepine; Female; Humans; Lamotrigine; Phenobarbital; Pregnancy; Pregnancy Com | 2013 |
A case series of patients with lamotrigine toxicity at one center from 2003 to 2012.
Topics: Adrenergic Uptake Inhibitors; Adult; Arrhythmias, Cardiac; Child, Preschool; Dopamine Uptake Inhibit | 2013 |
[Hashimoto encephalopathy].
Topics: Adrenal Cortex Hormones; Adult; Anticonvulsants; Antipsychotic Agents; Autoantibodies; Brain Disease | 2013 |
[Kinetogenic reflex epilepsy associated to masturbatory movements].
Topics: Anticonvulsants; Electromyography; Hand; Hippocampus; Humans; Lamotrigine; Male; Masturbation; Media | 2013 |
Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice.
Topics: Animals; Anticonvulsants; Avoidance Learning; Benzoxazines; Brain; Cannabinoid Receptor Agonists; Ca | 2013 |
[Clinical efficacy and pharmacokinetics of lamotrigine for childhood-onset intractable epilepsy].
Topics: Adolescent; Age of Onset; Child; Drug Therapy, Combination; Female; Humans; Lamotrigine; Male; Seizu | 2014 |
Hypokalemia and hypomagnesaemia related to levetiracetam use.
Topics: Adult; Anticonvulsants; Humans; Hypokalemia; Lamotrigine; Levetiracetam; Magnesium; Male; Nephritis, | 2014 |
The efficacy of the newer antiepileptic drugs in controlling seizures in pregnancy.
Topics: Anticonvulsants; Female; Fructose; Humans; Lamotrigine; Levetiracetam; Piracetam; Pregnancy; Registr | 2014 |
Conversion from immediate-release to extended-release lamotrigine improves seizure control.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Drug Delivery Sys | 2014 |
Lamotrigine can be beneficial in patients with Dravet syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsies, Myoclonic; Humans; Lamotrigine; Male; Seizures; Tria | 2015 |
Validation of a multigenic model to predict seizure control in newly treated epilepsy.
Topics: Adult; Algorithms; Anticonvulsants; Artificial Intelligence; Australia; Biomarkers, Pharmacological; | 2014 |
Rapid throughput analysis demonstrates that chemicals with distinct seizurogenic mechanisms differentially alter Ca2+ dynamics in networks formed by hippocampal neurons in culture.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Calcium; Cells, Cultured; High-Throughput Screening Assay | 2015 |
Effects of Chronic Lamotrigine Administration on Maximal Electroshock- Induced Seizures in Mice.
Topics: Animals; Anticonvulsants; Avoidance Learning; Blood Chemical Analysis; Brain; Chromatography, High P | 2015 |
Synergistic effect of docosahexaenoic acid on anticonvulsant activity of valproic acid and lamotrigine in animal seizure models.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Docosahexaenoic Acids; Dose-Response Relationship, | 2015 |
Comparative Long-Term Effectiveness of a Monotherapy with Five Antiepileptic Drugs for Focal Epilepsy in Adult Patients: A Prospective Cohort Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Epilepsies, Partial; Fem | 2015 |
Influence of MPEP (a selective mGluR5 antagonist) on the anticonvulsant action of novel antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Animals; Anticonvulsants; Brain; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, | 2016 |
Concomitant lamotrigine use is associated with decreased efficacy of the ketogenic diet in childhood refractory epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Combined Modality Therapy; Diet, Ketogenic; Dr | 2015 |
Pharmacological and neuroethological study of the acute and chronic effects of lamotrigine in the genetic audiogenic seizure hamster (GASH:Sal).
Topics: Animals; Anticonvulsants; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Epil | 2017 |
[Recurrent seizures of unknown aetiology].
Topics: Adult; Amnesia; Anticonvulsants; C-Peptide; Confusion; Endosonography; Female; Glucose Tolerance Tes | 2016 |
[Psychogenic non-epileptic seizures: issues of comorbidity in the diagnosis and treatment].
Topics: Adult; Anticonvulsants; Bipolar Disorder; Brain; Comorbidity; Electroencephalography; Epilepsy; Huma | 2016 |
Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Longitu | 2018 |
Influence of xanthotoxin (8-methoxypsoralen) on the anticonvulsant activity of various novel antiepileptic drugs against maximal electroshock-induced seizures in mice.
Topics: Acetamides; Animals; Anticonvulsants; Carbamazepine; Drug Synergism; Electroshock; Fructose; Lacosam | 2016 |
Efficacy and tolerability of anti-epileptic drugs-an internet study.
Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Epilepsy; Female; Humans; Internet; Lamotrigine; | 2017 |
Epilepsy with myoclonic absences: Electroclinical characteristics in a distinctive pediatric epilepsy phenotype.
Topics: Anticonvulsants; Brain; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Electroe | 2016 |
Anti-Epileptic Drug Combination Efficacy in an In Vitro Seizure Model - Phenytoin and Valproate, Lamotrigine and Valproate.
Topics: Animals; Anticonvulsants; Drug Combinations; Drug Interactions; Female; Hippocampus; In Vitro Techni | 2017 |
Vigabatrin, lamotrigine, topiramate and serum carnitine levels.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Female; Fructose; Humans; Infant; L | 2008 |
Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsies, Partial; E | 2009 |
Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism.
Topics: Anticonvulsants; Data Collection; Female; Humans; Lamotrigine; Levetiracetam; Middle Aged; Phenobarb | 2009 |
Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.
Topics: Animals; Anticonvulsants; Avoidance Learning; Behavior, Animal; Brain; Carbamates; Carbamazepine; Di | 2009 |
Association of lamotrigine and valproate in refractory epilepsies of children and adolescents.
Topics: Adolescent; Age Distribution; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; E | 2008 |
NA+, K+-ATPase activity in the brain of the rats with kainic acid-induced seizures: influence of lamotrigine.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Cerebral Cortex; Disease Models, Animal; Electroe | 2008 |
Intravenous immunoglobulin in the treatment of lamotrigine- induced toxic epidermal necrolysis.
Topics: Blister; Child; Exanthema; Female; Fever; Humans; Immunoglobulins, Intravenous; Lamotrigine; Seizure | 2008 |
A case with Stevens Johnson syndrome triggered by combination of clobazam, lamotrigine, and valproic acid treatment.
Topics: Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Drug Therapy, Combination; Follow-Up S | 2009 |
A case of maternal herpes simplex virus encephalitis during late pregnancy.
Topics: Acyclovir; Adult; Anticonvulsants; Antiviral Agents; Brain; Encephalitis, Herpes Simplex; Female; He | 2009 |
[Neonatal seizures caused by lamotrigin withdrawal?].
Topics: Adult; Anticonvulsants; Female; Humans; Infant, Newborn; Lamotrigine; Male; Maternal-Fetal Exchange; | 2009 |
The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat.
Topics: Animals; Anticonvulsants; Biophysics; Cell Line, Transformed; Dialysis; Disease Models, Animal; Dose | 2009 |
Life-threatening organ failure after lamotrigine therapy.
Topics: Anticonvulsants; Child; Contraindications; Drug Therapy, Combination; Exanthema; Female; Fever; Huma | 2009 |
Efficacy of anti-epileptic drugs in patients with gliomas and seizures.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Carbamazepine; Drug Therapy, Combination; Female; Follow-Up | 2009 |
End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients.
Topics: Adult; Affective Symptoms; Agoraphobia; Anticonvulsants; Bipolar Disorder; Depression; Epilepsy; Fem | 2009 |
Effect of ethacrynic acid on the anticonvulsant activity of the second-generation antiepileptics against maximal electroshock-induced seizures in mice.
Topics: Analysis of Variance; Animals; Anticonvulsants; Avoidance Learning; Brain; Brain Chemistry; Carbamaz | 2009 |
Effect of carbamazepine and lamotrigine on cognitive function and oxidative stress in brain during chemical epileptogenesis in rats.
Topics: Animals; Anticonvulsants; Avoidance Learning; Brain; Carbamazepine; Catalase; Cognition; Cognition D | 2010 |
Lamotrigine and absence seizures: new indication. Try valproic acid first.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Approval; Epilepsy, Absence; Europe; Huma | 2009 |
Effects of lamotrigine and topiramate on hippocampal neurogenesis in experimental temporal-lobe epilepsy.
Topics: Adult Stem Cells; Animals; Anticonvulsants; Cell Proliferation; Cell Survival; Chronic Disease; Dend | 2010 |
Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Carbamazepine; Disease Models, Animal; Dopamine Antago | 2010 |
Concurrent use of lamotrigine and electroconvulsive therapy.
Topics: Adult; Aged; Anticonvulsants; Combined Modality Therapy; Electroconvulsive Therapy; Female; Humans; | 2011 |
Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves.
Topics: Animals; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; | 2010 |
Lyell syndrome and epileptic seizures after confusion between Lamictal and Lamisil.
Topics: Anticonvulsants; Antifungal Agents; Epilepsy; Humans; Lamotrigine; Medication Errors; Naphthalenes; | 2010 |
Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice.
Topics: Animals; Anticonvulsants; Brain; Bupropion; Dopamine Uptake Inhibitors; Dose-Response Relationship, | 2011 |
Regression of stroke-like lesions in MELAS-syndrome after seizure control.
Topics: Adult; Anticonvulsants; Cerebral Cortex; Diagnosis, Differential; Electroencephalography; Female; Hu | 2010 |
Outcome of lamotrigine treatment in juvenile myoclonic epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Female; Humans; Lamotrigine; Male; Myoclonic Epilepsy, Juvenile; | 2011 |
Effect of lamotrigine, oxcarbazepine and topiramate on cognitive functions and oxidative stress in PTZ-kindled mice.
Topics: Animals; Anticonvulsants; Carbamazepine; Catalase; Cognition Disorders; Disease Models, Animal; Drug | 2011 |
Valproate treatment after liver transplant in a patient with Lennox-Gastaut syndrome.
Topics: Anticonvulsants; Chemical and Drug Induced Liver Injury; Electroencephalography; Female; Fructose; H | 2011 |
Cerebral abscess due to an abnormal drainage of the superior vena cava.
Topics: Adult; Angiography; Anti-Bacterial Agents; Anticonvulsants; Brain Abscess; Echocardiography; Epileps | 2011 |
Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Electroencephalo | 2011 |
Epileptic seizure induced by fennel essential oil.
Topics: Adult; Anticonvulsants; Epilepsy; Epilepsy, Tonic-Clonic; Female; Foeniculum; Humans; Lamotrigine; O | 2011 |
Lamotrigine is favourable for startle-induced seizures.
Topics: Activities of Daily Living; Age of Onset; Anticonvulsants; Atrophy; Brain; Child; Drug Eruptions; El | 2011 |
Possible acute myocardial infarction in a hypothermic patient.
Topics: Acute Disease; Anticonvulsants; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Drug Overdose; | 2011 |
[Lamotrigine-induced sleep behavior disturbance in a case with intractable epilepsy].
Topics: Adolescent; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilepsy; | 2011 |
Case files of the University of California San Francisco Medical Toxicology Fellowship: lamotrigine toxicity.
Topics: Anticonvulsants; Drug Overdose; Excitatory Amino Acid Antagonists; Humans; Lamotrigine; Male; Middle | 2012 |
Are proprioceptive-induced reflex seizures epileptically-enhanced stretch reflex manifestations?
Topics: Age of Onset; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsy, Reflex; Femal | 2012 |
Lamotrigine ameliorates seizures and psychiatric comorbidity in a rat model of spontaneous absence epilepsy.
Topics: Animals; Anticonvulsants; Anxiety Disorders; Comorbidity; Depressive Disorder; Disease Models, Anima | 2012 |
Synergistic interaction between valproate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Lamotri | 2002 |
Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist.
Topics: Animals; Anticonvulsants; Cell Death; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glycin | 2002 |
Coadministration of gabapentin or MK-801 with lamotrigine slows tolerance to its anticonvulsant effects on kindled seizures.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dizocilpine Maleate; Drug T | 2003 |
Effects of lamotrigine and levetiracetam on seizure development in a rat amygdala kindling model.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Electric Stimulation; Electrodes, Implanted; K | 2003 |
Synergistic interaction between felbamate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Drug Synergism; | 2003 |
Relationship between plasma and brain levels and the anticonvulsant effect of lamotrigine in rats.
Topics: Animals; Anticonvulsants; Brain; Electroshock; Lamotrigine; Male; Rats; Rats, Wistar; Seizures; Tria | 2003 |
Evaluation of antiepileptic activity of aspirin in combination with newer antiepileptic lamotrigine in mice.
Topics: Animals; Anticonvulsants; Aspirin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Co | 2003 |
Synthesis and pharmacological evaluation of newer substituted benzoxazepine derivatives as potent anticonvulsant agents.
Topics: Animals; Anticonvulsants; Benzazepines; Dose-Response Relationship, Drug; Electroshock; Lamotrigine; | 2004 |
Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat.
Topics: Animals; Anticonvulsants; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Dose-Response R | 2004 |
Frontal lobe seizures and uveitis associated with acute human parvovirus B19 infection.
Topics: Acute Disease; Anti-Inflammatory Agents; Anticonvulsants; Brain; Carbamazepine; Child, Preschool; El | 2004 |
Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug | 2004 |
Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy.
Topics: Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Electromyography; Epileps | 2004 |
Levetiracetam induces a rapid and sustained reduction of generalized spike-wave and clinical absence.
Topics: Adult; Anticonvulsants; Delta Rhythm; Dose-Response Relationship, Drug; Drug Administration Schedule | 2004 |
Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Bipolar Disorder; Carbamazepine; Central Nervous Syst | 2005 |
Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis.
Topics: Animals; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Electroshoc | 2005 |
Pharmacodynamic and pharmacokinetic interaction studies of loreclezole with felbamate, lamotrigine, topiramate, and oxcarbazepine in the mouse maximal electroshock seizure model.
Topics: Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Disease Models, Animal; Drug Interactions | 2005 |
Valproic acid, but not lamotrigine, suppresses seizure-induced c-fos and c-Jun mRNA expression.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Flurothyl; Gene Expression Regulation; In Situ Hy | 2005 |
Hyperprolactinemia presenting with encephalomalacia-associated seizure disorder and infertility: a novel application for bromocriptine therapy in reproductive endocrinology.
Topics: Adult; Anticonvulsants; Brain; Bromocriptine; Encephalomalacia; Hormone Antagonists; Humans; Hyperpr | 2005 |
The use of lamotrigine and other antiepileptic drugs in paediatric patients at a Malaysian hospital.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cost-Benefit Analysis; D | 2005 |
Eosinophilic hepatitis caused by lamotrigine.
Topics: Adult; Anticonvulsants; Chemical and Drug Induced Liver Injury; Eosinophilia; Female; Humans; Lamotr | 2006 |
Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation.
Topics: Activities of Daily Living; Adolescent; Adult; Anticonvulsants; Drug Tolerance; Epilepsy; Female; Hu | 2006 |
Lamotrigine-induced seizures in a child: case report and literature review.
Topics: Anticonvulsants; Humans; Infant; Lamotrigine; Male; Seizures; Tablets; Treatment Outcome; Triazines | 2007 |
Self-poisoning with lamotrigine and pregabalin.
Topics: Adult; Anticonvulsants; Drug Overdose; gamma-Aminobutyric Acid; Humans; Lamotrigine; Male; Pregabali | 2007 |
Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Anticonvulsants; Canada; Child; Child, P | 2007 |
Lamotrigine-induced bilateral ballism.
Topics: Adolescent; Anticonvulsants; Dyskinesias; Functional Laterality; Humans; Lamotrigine; Male; Seizures | 2007 |
Seizure-freedom with combination therapy in localization-related epilepsy.
Topics: Adult; Anticonvulsants; Brain; Carbamazepine; Drug Therapy, Combination; Female; Frontal Lobe; Fruct | 2008 |
Lamotrigine differently modulates 7-nitroindazole and L-arginine influence on rat maximal dentate gyrus activation.
Topics: Animals; Anticonvulsants; Arginine; Dentate Gyrus; Electric Stimulation; Enzyme Inhibitors; Indazole | 2008 |
Seizures and altered mental status after lamotrigine overdose.
Topics: Adult; Anticonvulsants; Consciousness; Drug Overdose; Humans; Lamotrigine; Seizures; Triazines | 2007 |
Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Drug Therapy, Co | 2008 |
Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Dose-Response Relationship, Drug; D | 2008 |
In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Behavior, Animal; Calcium Channel | 2008 |
Sturge-Weber syndrome, without a facial port-wine stain, with epilepsy onset in the fifth decade.
Topics: Anticonvulsants; Electroencephalography; Epilepsy; Female; Hearing Loss, Conductive; Humans; Lamotri | 2008 |
Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents.
Topics: Animals; Anticonvulsants; Brain Ischemia; Carbamazepine; Cerebral Arteries; Electrophysiology; Elect | 1994 |
Interaction of lamotrigine with sodium valproate.
Topics: Adult; Aged; Anticonvulsants; Child; Drug Interactions; Drug Therapy, Combination; Female; Humans; L | 1993 |
Lamotrigine encephalopathy.
Topics: Anticonvulsants; Astrocytoma; Brain Diseases; Brain Neoplasms; Drug Interactions; Female; Frontal Lo | 1996 |
Lamotrigine potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Diazepam; Drug Synergism; Female; Lamotrigine; Male; | 1996 |
Treatment with high doses of lamotrigine in children and adolescents with refractory seizures.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Eruptio | 1997 |
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
Suspected lamotrigine-induced toxic epidermal necrolysis.
Topics: Aged; Anticonvulsants; Humans; Lamotrigine; Male; Seizures; Stevens-Johnson Syndrome; Triazines | 1997 |
Effects of felbamate, gabapentin and lamotrigine on seizure parameters and excitability in the rat hippocampus.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, | 1997 |
NMDA receptor-mediated pilocarpine-induced seizures: characterization in freely moving rats by microdialysis.
Topics: Animals; Anticonvulsants; Atropine; Convulsants; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; H | 1997 |
Seizures, ventricular tachycardia, and rhabdomyolysis as a result of ingestion of venlafaxine and lamotrigine.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Cyclohexanols; Electrocardiography | 1997 |
A rash of oversights.
Topics: Adolescent; Age Factors; Anticonvulsants; Carbamazepine; Drug Eruptions; Drug Interactions; Drug Lab | 1997 |
[Anticonvulsant and neurotoxic effects of lamiktal (lamotrigine) in combination with other anticonvulsants].
Topics: Animals; Anticonvulsants; Drug Synergism; Electroshock; Lamotrigine; Mice; Seizures; Triazines | 1997 |
Lamotrigine inhibits the in situ activity of tyrosine hydroxylase in striatum of audiogenic seizure-prone and audiogenic seizure-resistant Balb/c mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Animals; Corpus Striatum; Dopamine; Enzyme Inh | 1997 |
Effects of lamotrigine and conventional antiepileptic drugs on amygdala- and hippocampal-kindled seizures in rats.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Electroencephal | 1998 |
Anticonvulsant and glutamate release-inhibiting properties of the highly potent metabotropic glutamate receptor agonist (2S,2'R, 3'R)-2-(2',3'-dicarboxycyclopropyl)glycine (DCG-IV).
Topics: Amygdala; Animals; Anticonvulsants; Aspartic Acid; Cerebral Cortex; Cyclopropanes; Glutamic Acid; Gl | 1998 |
Efficacy of lamotrigine in refractory neonatal seizures.
Topics: Anticonvulsants; Drug Resistance; Electroencephalography; Female; Humans; Infant, Newborn; Lamotrigi | 1999 |
Lamotrigine-induced blepharospasm.
Topics: Anticonvulsants; Blepharospasm; Humans; Lamotrigine; Male; Middle Aged; Seizures; Triazines | 1999 |
Tolerance to the anticonvulsant effects of lamotrigine on amygdala kindled seizures: cross-tolerance to carbamazepine but not valproate or diazepam.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Diazepam; Disease Models, Animal; Dose-Response R | 2000 |
Hyponatraemia associated with lamotrigine in cranial diabetes insipidus.
Topics: Adolescent; Anticonvulsants; Child; Deamino Arginine Vasopressin; Diabetes Insipidus, Neurogenic; Do | 2000 |
Prolonged toxic epidermal necrolysis due to Lamotrigine.
Topics: Adult; Anticonvulsants; Drug Interactions; Humans; Lamotrigine; Male; Seizures; Stevens-Johnson Synd | 2000 |
Stimulating consciousness and cognition following severe brain injury: a new potential clinical use for lamotrigine.
Topics: Activities of Daily Living; Adult; Aged; Anticonvulsants; Brain Injuries; Cognition; Excitatory Amin | 2000 |
Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy.
Topics: Amygdala; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Electr | 2000 |
The tolerability of lamotrigine in elderly patients with epilepsy.
Topics: Aged; Anticonvulsants; Clinical Trials as Topic; Databases, Factual; Drug Tolerance; Epilepsy; Femal | 2001 |
Intrinsic optical signals and electrographic seizures in the rat limbic system.
Topics: 4-Aminopyridine; Action Potentials; Animals; Anticonvulsants; Axotomy; Electric Stimulation; Electro | 2001 |
Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders.
Topics: Amygdala; Animals; Anticonvulsants; Excitatory Amino Acid Antagonists; GABA-A Receptor Antagonists; | 2002 |
Anticonvulsant action of lamotrigine during ontogenesis in rats.
Topics: Aging; Animals; Anticonvulsants; Epilepsy, Tonic-Clonic; Injections, Intraperitoneal; Lamotrigine; M | 1992 |
The effect of lamotrigine upon development of cortical kindled seizures in the rat.
Topics: Animals; Anticonvulsants; Cerebral Cortex; Electric Stimulation; Electroencephalography; Kindling, N | 1991 |
Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures.
Topics: Adult; Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Drug Tolerance; Humans; | 1989 |